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explanation and elaboration
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Mendelian randomisation (MR) studies 
allow a better understanding of the 
causal effects of modifiable exposures 
on health outcomes, but the published 
evidence is often hampered by 
inadequate reporting. Reporting 
guidelines help authors effectively 
communicate all critical information 
about what was done and what was 
found. STROBE-MR (strengthening the 
reporting of observational studies in 
epidemiology using mendelian 
randomisation) assists authors in 
reporting their MR research clearly and 
transparently. Adopting STROBE-MR 
should help readers, reviewers, and 
journal editors evaluate the quality of 
published MR studies. This article 
explains the 20 items of the STROBE-
MR checklist, along with their meaning 
and rationale, using terms defined in a 
glossary. Examples of transparent 
reporting are used for each item to 
illustrate best practices.
Observational epidemiology often examines the 
associations between exposures and health outcomes. 
However, such associations reported in epidemiological 
studies are often not reliable estimates of causal 
effects, and can be produced by confounding (that is, 
by another factor that affects both the outcome and 
exposure)1-3 or by other forms of bias. For example, 
alcohol consumption might be related to many 
potential confounding factors, including smoking, 
an unhealthy diet, and limited exercise. In turn, ill 
health could be related to a reduction or cessation 
of alcohol consumption, introducing potential bias 
due to reverse causality, when interest is in studying 
the effect of alcohol consumption on subsequent 
health.4 5 Several approaches have been developed 
with the aim of mitigating such biases.6 For example, 
instrumental variable methods rely on an external 
factor that determines the exposure of interest but is 
not associated with the outcome other than through its 
effect on the exposure.6 7
Over the past decade, advances in genetic 
technologies have enabled the identification of 
thousands of reproducible associations between 
genetic variation and relevant exposures, traits, and 
health outcomes. These genetic variations can be 
used as instrumental variables to analyse the effect 
of modifiable exposures on diseases through a study 
method termed mendelian randomisation (MR).8 
MR studies use genetic variants robustly related to 
modifiable exposures to understand the influence of 
the exposure on various health, social, and economic 
outcomes. Genetic variation is essentially randomly 
inherited from parents to offspring at conception, 
and consequently, many factors that confound the 
association between the exposure and outcome 
cannot affect the genetic variants. Similarly, genetic 
variants are generally not influenced by the outcome 
and therefore, by reverse causation. MR thus provides 
an opportunity to study the association between 
exposures and outcomes while reducing potential bias 
from confounding and reverse causation.9
These features make genetic variants suitable 
candidates as instrumental variables, which can help 
estimate the causal effects of modifiable exposures 
on outcomes.7 For example, the rs1229984 variant 
in the alcohol dehydrogenase 1B gene (ADH1B) has 
been used as an instrument to investigate the causal 
role of alcohol in cardiovascular disease.10 Given these 
advantages, MR studies have increased in popularity 
and have begun to inform understanding of disease 
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SUMMARY POINTS
In observational epidemiology, mendelian randomisation (MR) studies provide 
an opportunity to study the causal association between an exposure and an 
outcome while reducing the risk of certain biases
Little consensus exists around the reporting of MR studies, and the quality of 
reporting of these studies has been inconsistent; many MR study reports do not 
state or examine the various assumptions of MR and report insufficient details on 
the data sources
STROBE-MR (strengthening the reporting of observational studies in 
epidemiology using mendelian randomisation), a checklist of 20 reporting items, 
has been developed for the communication of MR studies
This article explains the rationale of these checklist items and provides examples 
of transparent reporting
MR study authors, reviewers, and journal editors are encouraged to use STROBE-
MR to improve the reporting of these studies
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causation. MR is not limited to studies using genetic 
variants to generate instrumental variable estimates 
(box 1, table 1); however, these studies dominate the 
literature. A glossary of terms commonly used in MR 
is given in table 2. Additional terms and explanations 
can be found in a comprehensive open access MR 
dictionary.21
Strengthening the reporting of MR studies
Despite the growth in MR applications and methods 
and the increasing relevance of MR findings, little 
consensus exists around the reporting of MR studies. 
As a result, the quality of reporting of these studies has 
been inconsistent. Empirical evidence22-24 indicates 
that many reports of MR studies do not clearly state or 
examine the various assumptions of MR methods and 
report insufficient details on the data sources, which 
makes the quality and reliability of the results difficult 
to evaluate.
The STROBE (strengthening the reporting of 
observational studies in epidemiology) guidelines 
for observational research25 26 were developed 
for the three main study designs in epidemiology 
(cohort, case-control, and cross sectional studies). 
Some STROBE items are either too general or do not 
apply to MR studies, while other items relevant to 
MR studies are missing. To improve reporting MR 
studies, we developed a separate checklist of items 
motivated by the STROBE guidelines but explicitly 
focused on the MR study design, resulting in the 
STROBE-MR statement (strengthening the reporting 
of observational studies in epidemiology using 
mendelian randomisation27; table 3). Similar to the 
STROBE checklist, the STROBE-MR items relate to the 
title, abstract, introduction, methods, results, and 
discussion sections of articles. 
Development, scope, and intended use of STROBE-MR
Described in detail elsewhere,27 we established 
this initiative in 2018, following guidance for 
the development of medical research reporting 
guidelines.28 We invited a group of experts, ranging 
from MR methodologists and authors of previous 
reporting guidelines to frequent MR study design 
users and scientific journal editors to participate in a 
workshop. The group met for a face-to-face meeting in 
Bristol, UK, over two days in May 2019 to discuss the 
empirical evidence on reporting quality of MR studies 
and draft the checklist items. The draft checklist 
was published as a preprint in July 2019,29 and 
debated on the preprint platform, social media, and a 
dedicated session at the 4th International Mendelian 
Randomisation Conference.30 We revised the checklist 
in the light of the comments received and produced an 
article presenting the STROBE-MR statement.27
The STROBE-MR reporting guidelines are meant to 
apply to studies that use properties of germline genetic 
variants to strengthen causal inference regarding 
possible effects of potentially modifiable exposures on 
outcomes. The two principal types of MR studies are 
Box 1: Scope of mendelian randomisation (MR) and the STROBE-MR checklist
While MR generally uses genetic variation as the instrumental variable, MR is not limited to such studies. Indeed, the term “mendelian 
randomisation” was introduced in 1991 for investigations of bone marrow transplantation in the treatment of childhood malignancies.11 12 The 
basic notion was that if a child had an HLA compatible sibling, that child was more likely to receive a bone marrow transplant than a child with no 
compatible sibling. Analysing outcomes according to whether the child has such a sibling (optimally taking the number of siblings into account) 
is analogous to an intention-to-treat analysis in a randomised clinical trial.11 12 Having an HLA compatible sibling (as a matter of chance) could 
also serve as a genetic instrument for bone marrow transplantation, and so might be used to infer effects of transplantation on cancer outcomes. 
This approach has continued to be used.13-15 Initially, MR was defined as the use of germline genetic variation to strengthen causal inference for 
the influence of modifiable exposures on risk of disease or other outcomes.16 This wider definition includes, for example, studies of gene-by-
covariate interaction (often with environment as the covariate), for which the interaction cannot be viewed as an instrument for the exposure of 
interest.17 18 Other study designs, such as twin studies, also use the basic principles of mendelian genetics and so can be considered a form of 
MR. One such example used a male co-twin as an indicator of (on average) higher antenatal testosterone to appraise the effect of testosterone on 
neurodevelopmental traits.19 MR studies range from a simple test of an association between single nucleotide polymorphisms and outcome, which 
can provide evidence as to whether an exposure affects a disease, to a specific effect estimate from an instrumental variable analysis.
The STROBE-MR (strengthening the reporting of observational studies in epidemiology using mendelian randomisation) guidelines are aimed 
at the (currently) large majority of MR studies that are implemented within an instrumental variable framework. For MR studies that do not use an 
instrument for the exposure (such as those of gene-by-environment interaction) or MR studies that use genetic variants in an instrumental variable 
framework but do not report instrumental variable estimates (such as those of sibling compatibility for transplantation), some items of STROBE-MR 
will not apply, but the checklist still provides useful guidance. Table 1 gives an overview of study designs addressed and not addressed by 
STROBE-MR.
Table 1 | Overview of study designs addressed or not addressed by STROBE-MR checklist
Study types addressed Study types not addressed
One sample MR studies Genome wide association studies
Two sample MR studies Sequencing studies
MR studies after a genome wide association study and reported in the same article Expression studies
One or two sample MR studies with multiple exposures* or multiple outcomes (or both) Traditional observational epidemiology studies
Partially applies to MR studies not using genetic variants as instruments for an exposure and those not reporting instrumental variable approaches
MR=mendelian randomisation; STROBE-MR=strengthening the reporting of observational studies in epidemiology using mendelian randomisation.
*For example, MR studies of circulating protein levels often test the association of hundreds of circulating protein levels, measured on high-throughput assays, with specific outcomes.
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one sample MR and two sample MR. In a one sample 
MR study, the associations between the genetic variant 
and exposure and between the genetic variant and 
outcome are both measured in the same sample. In 
a two sample MR study, these two associations are 
measured in separate samples. MR studies can also 
use either individual level or summary level data to 
derive or apply the weights for each single nucleotide 
polymorphism (SNP). Two sample MR studies are most 
commonly conducted with summary level data, where 
the weights are derived from the first sample, which 
are then applied in the second sample to estimate the 
gene-outcome association. Summary sample weights 
for the association of genetic variants with an exposure 
can also be used in an individual level data analysis 
of the association of these variants with the outcome. 
Table 1 (in box 1) outlines the study designs covered 
and those not covered by the STROBE-MR guidelines.
Table 2 | Glossary of commonly used terms in mendelian randomisation (MR)
Term Explanation
MR A method that uses genetic variation to strengthen causal inference regarding modifiable exposures (eg, body mass index, alcohol 
consumption, plasma lipoprotein, time spent in education, C reactive protein level, or serum 25-hydroxyvitamin D) influencing risk of 
disease or other outcomes. Most MR studies are implemented within an instrumental variable framework, using genetic variants as 
instrumental variables.
One sample MR A type of MR study in which one sample of individuals is used to estimate the genetic variant-exposure and genetic variant-outcome 
associations. This approach requires that the genetic variants, exposures, and outcomes are all measured in the same sample and that 
individual level data are available on all participants.
Two sample MR A type of MR study in which the genetic variant-exposure and genetic variant-outcome associations are estimated in different samples 
and combined using meta-analysis tools. This approach requires summary level statistics of the association of each genetic variant in 
the two samples. It does not require individual level data.
Bidirectional MR A type of MR study in which one set of instrumental variables is used to test the effect of the exposure on the outcome and a separate 
set of instrumental variables is used to test the effect of the outcome on the exposure. This approach allows for a better understanding 
of the direction of the causal effect.
Instrumental variables Variables associated with the exposure of interest that are not related to confounders, and that affect the outcome only through the 
exposure.
Instrumental variable assumptions 
(core assumptions in MR studies)
Include assumptions for relevance (the genetic variants are associated with the exposure of interest); independence (the genetic 
variants share no unmeasured cause with the outcome); and exclusion restriction (the genetic variants do not affect the outcome except 
through their potential effect on the exposure of interest).
Assessment of instrumental variable 
assumptions
Various tests can assess the plausibility of instrumental variable assumptions (eg, a test of whether potential confounders or pleiotropic 
mechanisms are associated with the genetic variant; see below for more examples). Only the first assumption (relevance) can be tested 
conventionally; the validity of the other assumptions cannot be guaranteed. However, tests can provide evidence that they are unlikely 
to hold (that is, these assumptions cannot be verified, but sometimes can be falsified).
Gene environment equivalence The notion that differences in an exposure induced by genetic variation will produce the same downstream effects on health outcomes 
as differences in the exposure produced by environmental influences.
Genetic variant A variation in the DNA sequence that is found within a population. Typically, a single nucleotide polymorphism (SNP).
Single nucleotide polymorphism 
(SNP)
A genetic variant in which a single base pair in the DNA varies across the population, at an appreciable frequency. SNPs typically have 
two alleles (eg, adenine, cytosine, guanine, or thiamine). If the SNP is associated with the trait, then one allele will be associated with a 
higher value of the trait, the other with a lower value. In MR studies, SNPs are the most common genetic variants used as instrumental 
variables for a modifiable exposure.
Strand alignment Strand alignment ensures that the alleles in the exposure GWAS (genome wide association study) and the outcome GWAS are measured 
on the same DNA strand. An issue could arise when the SNPs are palindromic (that is, guanine/cytosine and adenine/thymine SNPs), 
which would look the same on both DNA strands. Without ensuring that the exposure and outcome GWAS report the same strand, such 
SNPs can introduce ambiguity as to whether both the exposure and outcome GWAS are reporting the association with the same effect 
allele.
Allele score A single variable produced by combining information from several SNPs that are associated with a trait or phenotype (eg, blood 
pressure), which can be used to predict the exposure in a MR study. An allele score is sometimes also referred to as genetic risk score, 
polygenic score, or genetic prediction score.
Linkage disequilibrium The non-random association of alleles at two or more loci, which normally occurs within a small region of the genome in the general 
population and is a potential source of bias in MR studies.
r2 A measure of the linkage disequilibrium between two genetic loci to quantify their correlation (value of 1 denotes perfect correlation). 
This measure should not be confused with the R2 value (representing the proportion of variation in the exposure variable explained by 
the genetic variant), which can be used to calculate instrument strength.
Test of instrument strength Measure of the association between the genetic variant and the exposure. The strength is typically tested using the partial F statistic or 
the R2.
Test for difference Assessment of the difference between the multivariable adjusted phenotypic association and MR estimates (eg, Hausman test). These 
tests indicate whether there is any evidence that the estimates differ, over and above estimation error.
Horizontal pleiotropy When genetic variants affect the outcome via pathways independent of the exposure. This event is a violation of the exclusion restriction 
assumption and a source of bias in MR studies.
Weak instrument bias If genetic variants used as instrumental variables are only weakly associated with the exposure of interest, they are said to be “weak 
instruments,” and then the MR estimates can be biased. Although a partial F statistic is commonly used as an indicator of potential weak 
instrument bias (when F is <10 in an analysis of one sample), weak instrument bias can still occur at values greater than 10. This rule of 
thumb is analogous to the false dichotomisation of P values as either significant or not significant at an arbitrary cut-off value such as 
P=0.05.20
Collider bias Bias that can occur when conditioning on a common effect of the genetic variant and another key variable, such as the outcome. This 
conditioning can either occur statistically (eg, including a covariate that is caused by both the variant and outcome) or through the study 
sampling (eg, analysing a sample of patients in hospital, where admission is influenced by the variant and other factors).
Winner’s curse When the discovery estimates of the SNP-exposure associations tend to be over-estimated, which occurs when the statistically strongest 
associations—usually using a P value threshold—are selected from the discovery sample.
Data Can refer to either individual level data, such as measurements of participants’ phenotypes such as body mass index and genetic data, 
or SNP level phenotype association estimates (summary level data).
RESEARCH METHODS AND REPORTING
4 doi: 10.1136/bmj.n2233 | BMJ 2021;375:n2233 | the bmj
Item No Section Checklist item
1 Title and abstract Indicate mendelian randomisation (MR) as the study’s design in the title and/or the abstract if that is a main purpose of the study
Introduction
2 Background Explain the scientific background and rationale for the reported study. What is the exposure? Is a potential causal association 
between exposure and outcome plausible? Justify why MR is a helpful method to address the study question
3 Objectives State specific objectives clearly, including prespecified causal hypotheses (if any). State that MR is a method that, under specific 
assumptions, intends to estimate causal effects
Methods
4 Study design and data sources Present key elements of the study design early in the article. Consider including a table listing sources of data for all phases of the 
study. For each data source contributing to the analysis, describe the following:
a) Setting: Describe the study design and the underlying population, if possible. Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, and data collection, when available.
b) Participants: Give the eligibility criteria, and the sources and methods of selection of participants. Report the sample size, and 
whether any power or sample size calculations were carried out prior to the main analysis
c) Describe measurement, quality control, and selection of genetic variants
d) For each exposure, outcome, and other relevant variables, describe methods of assessment and diagnostic criteria for diseases
e) Provide details of ethics committee approval and participant informed consent, if relevant
5 Assumptions Explicitly state the three core instrumental variable assumptions for the main analysis (relevance, independence, and exclusion 
restriction), as well assumptions for any additional or sensitivity analysis
6 Statistical methods: main 
analysis
Describe statistical methods and statistics used
a) Describe how quantitative variables were handled in the analyses (that is, scale, units, model)
b) Describe how genetic variants were handled in the analyses and, if applicable, how their weights were selected
c) Describe the MR estimator (eg, two stage least squares, Wald ratio) and related statistics. Detail the included covariates and, in the 
case of two sample MR, whether the same covariate set was used for adjustment in the two samples
d) Explain how missing data were addressed
e) If applicable, indicate how multiple testing was addressed
7 Assessment of assumptions Describe any methods or prior knowledge used to assess the assumptions or justify their validity
8 Sensitivity analyses and 
additional analyses
Describe any sensitivity analyses or additional analyses performed (eg, comparison of effect estimates from different approaches, 
independent replication, bias analytic techniques, validation of instruments, simulations)
9 Software and pre-registration
a) Name statistical software and package(s), including version and settings used
b) State whether the study protocol and details were pre-registered (as well as when and where)
Results
10 Descriptive data
a) Report the numbers of individuals at each stage of included studies and reasons for exclusion. Consider use of a flow diagram
b) Report summary statistics for phenotypic exposure(s), outcome(s), and other relevant variables (eg, means, SDs, proportions)
c) If the data sources include meta-analyses of previous studies, provide the assessments of heterogeneity across these studies
d) For two sample MR: 
i. Provide justification of the similarity of the genetic variant-exposure associations between the exposure and outcome samples 
ii. Provide information on the number of individuals who overlap between the exposure and outcome studies
11 Main results
a) Report the associations between genetic variant and exposure, and between genetic variant and outcome, preferably on an 
interpretable scale
b) Report MR estimates of the association between exposure and outcome, and the measures of uncertainty from the MR analysis, on 
an interpretable scale, such as odds ratio or relative risk per SD difference
c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
d) Consider plots to visualise results (eg, forest plot, scatterplot of associations between genetic variants and outcome v between 
genetic variants and exposure)
12 Assessment of assumptions
a) Report the assessment of the validity of the assumptions
b) Report any additional statistics (eg, assessments of heterogeneity across genetic variants, such as I2, Q statistic, or E value)
13 Sensitivity analyses and additional analyses
a) Report any sensitivity analyses to assess the robustness of the main results to violations of the assumptions
b) Report results from other sensitivity analyses or additional analyses
c) Report any assessment of direction of causal association (eg, bidirectional MR)
d) When relevant, report and compare with estimates from non-MR analyses
e) Consider additional plots to visualise results (eg, leave-one-out analyses)
Discussion
14 Key results Summarise key results with reference to study objectives
15 Limitations Discuss limitations of the study, taking into account the validity of the instrumental variable assumptions, other sources of potential 
bias, and imprecision. Discuss both direction and magnitude of any potential bias and any efforts to address them
16 Interpretation
a) Meaning: Give a cautious overall interpretation of results in the context of their limitations and in comparison with other studies
b) Mechanism: Discuss underlying biological mechanisms that could drive a potential causal association between the investigated 
exposure and the outcome, and whether the gene-environment equivalence assumption is reasonable. Use causal language 
carefully, clarifying that instrumental variable estimates may provide causal effects only under certain assumptions
c) Clinical relevance: Discuss whether the results have clinical or public policy relevance, and to what extent they inform effect sizes of 
possible interventions
17 Generalisability Discuss the generalisability of the study results (a) to other populations, (b) across other exposure periods/timings, and (c) across 
other levels of exposure
Table 3 | STROBE-MR checklist of recommended items to address in reports of mendelian randomisation studies
(Continued)
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Purpose of this article
This explanation and elaboration (E&E) document is 
intended to complement the STROBE-MR statement.27 
The format follows that of previous reporting 
guidelines, such as the STROBE E&E document26; it 
aims to provide readers with a detailed explanation 
supporting each of the 20 items in the checklist and 
examples of transparent reporting. Examples of quality 
reporting for each checklist item have been identified 
from published MR studies.
This document should be considered as a reference 
for authors to understand better what is meant by each 
item in the accompanying checklist. The examples do 
not necessarily represent the ideal statement for each 
checklist item. Rather, they highlight the intended 
issue meant to be covered in each item in the checklist. 
The boxes and tables in this article contain more 
theoretical background pertaining to MR study designs 
and complement recommendations on reporting. 
Additional guidance on performing MR studies can be 
found elsewhere.31
Some examples were edited by removing citations 
and sections not related to the reported item. Items 
are divided into sections: title and abstract (item 1), 
introduction (items 2-3), methods (items 4-9), results 
(items 10-13), discussion (items 14-17), and other 
information (items 18-20; table 3). Some items have 
subparts that relate to the same topic (eg, item 10d only 
relates to a two sample MR study design). Additional 
examples are provided in web appendix 2. We advise 
authors to address all items in the checklist, even if 
some information is reported in their supplementary 
materials because of space restriction.
Title and abstract (item 1) 
Indicate MR as the study’s design in the title and/or the 
abstract if that is a main purpose of the study.
Title
Examples
“BMI as a Modifiable Risk Factor for Type 2 Diabetes: 
Refining and Understanding Causal Estimates Using 
Mendelian Randomization.”32
“Genome Wide Analyses of >200,000 Individuals 
Identify 58 Loci for Chronic Inflammation and 
Highlight Pathways that Link Inflammation and 
Complex Disorders.”33
Explanation
When MR has played a crucial role in the study design, 
the term “mendelian randomisation” should be 
included in the title. In some situations, MR is used 
as a follow-on analytical technique, when the primary 
analysis is not MR. In this case, there might be no need 
to directly include MR in the title but retain focus on 
the manuscript’s main objectives.
Abstract
Example
“Importance: Human genetic studies have indicated 
that plasma lipoprotein(a) (Lp[a]) is causally associated 
with the risk of coronary heart disease (CHD), but 
randomized trials of several therapies that reduce Lp(a) 
levels by 25% to 35% have not provided any evidence 
that lowering Lp(a) level reduces CHD risk.
“Objective: To estimate the magnitude of the 
change in plasma Lp(a) levels needed to have the 
same evidence of an association with CHD risk as a 
38.67-mg/dL (ie, 1-mmol/L) change in low-density 
lipoprotein cholesterol (LDL-C) level, a change that 
has been shown to produce a clinically meaningful 
reduction in the risk of CHD.
“Design, Setting, and Participants: A Mendelian 
randomisation analysis was conducted using 
individual participant data from 5 studies and with 
external validation using summarised data from 48 
studies. Population-based prospective cohort and 
case-control studies featured 20 793 individuals with 
CHD and 27 540 controls with individual participant 
data, whereas summarised data included 62 240 
patients with CHD and 127 299 controls. Data were 
analysed from November 2016 to March 2018.
“Exposures: Genetic LPA score and plasma Lp(a) 
mass concentration.
“Main Outcomes and Measures: Coronary heart 
disease.
“Results: Of the included study participants, 53% 
were men, all were of white European ancestry, and the 
mean age was 57.5 years. The association of genetically 
predicted Lp(a) with CHD risk was linearly proportional 
to the absolute change in Lp(a) concentration. A 10-
mg/dL lower genetically predicted Lp(a) concentration 
was associated with a 5.8% lower CHD risk (odds 
ratio [OR], 0.942; 95% CI, 0.933-0.951; P=3×10−37), 
whereas a 10-mg/dL lower genetically predicted LDL-C 
level estimated using an LDL-C genetic score was 
associated with a 14.5% lower CHD risk (OR, 0.855; 
95% CI, 0.818-0.893; P=2×10−12). Thus, a 101.5-mg/
dL change (95% CI, 71.0-137.0) in Lp(a) concentration 
had the same association with CHD risk as a 38.67-mg/
dL change in LDL-C level. The association of genetically 
predicted Lp(a) concentration with CHD risk appeared 
Item No Section Checklist item
Other information
18 Funding Describe sources of funding and the role of funders in the present study and, if applicable, sources of funding for the databases and 
original study or studies on which the present study is based
19 Data and data sharing Provide the data used to perform all analyses or report where and how the data can be accessed, and reference these sources in the 
article. Provide the statistical code needed to reproduce the results in the article, or report whether the code is publicly accessible 
and if so, where
20 Conflicts of interest All authors should declare all potential conflicts of interest
SD=standard deviation. This checklist is also available separately in web appendix 1.
Table 3 | Continued
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to be independent of changes in LDL-C level owing to 
genetic variants that mimic the relationship of statins, 
PCSK9 inhibitors, and ezetimibe with CHD risk.
“Conclusions and Relevance: The clinical benefit 
of lowering Lp(a) is likely to be proportional to the 
absolute reduction in Lp(a) concentration. Large 
absolute reductions in Lp(a) of approximately 100 mg/
dL may be required to produce a clinically meaningful 
reduction in the risk of CHD similar in magnitude to 
what can be achieved by lowering LDL-C level by 
38.67 mg/dL (ie, 1 mmol/L).”34 (Further examples are 
available in web appendix 2.)
Explanation
The abstract should provide an informative and 
balanced summary of what was done and what was 
found. This summary should be presented alongside 
critical issues in study design, including sources of data, 
exposures or outcomes, individual versus summary data 
and would (if possible) include the term “mendelian 
randomisation” to make the article discoverable as 
such. Results should be presented in a fully transparent 
manner and include both point estimates and their error 
(that is, not only P values) for the range of approaches 
applied. The word “causal” should be used carefully, 
because MR only provides estimates intended to inform 
our understanding of causal associations under specific 
assumptions. The abstract should be sufficiently 
detailed to act as a standalone part of the manuscript. 
When permitted by the journal, structured abstracts 
can provide clarity and help assure that all relevant 
information is included. Web appendix 2 includes 
additional examples of abstracts for one sample, two 
sample, and embedded MR studies.
Introduction
Background (item 2)
Explain the scientific background and rationale for 
the reported study. What is the exposure? Is causality 
between exposure and outcome plausible? Justify why 
MR is a helpful method to answer the study question.
Examples
“Epidemiologic studies have reported an increased 
risk of multiple sclerosis (MS) with earlier age at 
puberty, particularly among women. However, others 
failed to replicate this finding. Pubertal timing has 
complex interactions with weight status, whereby 
higher childhood adiposity leads to earlier puberty, 
which in turn is associated with higher adult body 
mass index (BMI). Because evidence supports a role for 
increased BMI in MS pathogenesis, at least part of the 
observed link between pubertal timing and MS might 
be explained by BMI. Some of the limitations faced 
by observational studies can be mitigated through 
instrumental variable methods, in which a variable 
is used as a proxy for an exposure to explore the 
effect of that exposure on an outcome. In Mendelian 
randomisation (MR), genetic variants are used as 
instrumental variables to test for a causal association 
between a risk factor and an outcome.”35
“Nonlinear relationships exist between risk factors 
and outcomes across biomedical research. Methods 
have been developed that help to estimate non-linear 
relationships between exposures such as BMI and 
cardiovascular disease . . . We estimated the localized 
average causal effects of BMI on each risk factor 
within quintiles of the distribution of BMI after the 
genetic component is subtracted (the IV [instrumental 
variable]-free BMI) and performed heterogeneity and 
trend tests on these values.”36
Explanation
While some authors have used MR to test the effect 
of exposures on many different outcomes without 
prior hypotheses,37 most MR studies are designed 
to assess a specific hypothesis that has arisen from 
previous studies. When using a specific hypothesis, the 
rationale for assessing the current hypothesis should be 
described, including the a priori expectation of the effect 
size. MR can be used to test causal null hypotheses or 
estimate point, period, or lifetime effects. The role of MR 
in assessing the study hypothesis should be delineated 
to orient readers to what specific gap in the literature 
can be addressed by applying MR methods to the study 
hypothesis.
Objectives (item 3)
State specific objectives clearly, including prespecified 
causal hypotheses (if any). State that MR is a method 
that, under specific assumptions, intends to estimate 
causal effects.
Example
“Objective: To evaluate the potential causal association 
between genetic variants related to elevated serum 
calcium levels and risk of coronary artery disease 
(CAD) and myocardial infarction using Mendelian 
randomization.”38
Explanation
Authors should clearly state that the study aims to 
estimate a causal effect of the specified exposure on 
the specified outcome. This section should define the 
key exposure(s) and outcome(s) of interest to orient 
readers, and state the overall study objectives.
Methods
Study design and data sources (item 4)
Present key elements of the study design early in the 
article. Consider including a table listing sources of 
data for all phases of the study.
Example
“Details of the contributing GWAS consortiums are 
listed in table 1 [see table 4]. The studies were selected 
for investigating traits related to cardiovascular or 
metabolic health, having the largest sample sizes, 
and consisting of the most similar populations while 
minimising sample overlap. Percentage sample 
overlap is presented in supplementary table S1. 
Subjective wellbeing was measured using any items 
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relating to happiness or positive affect and overall 
life satisfaction. GWAS of each component were meta-
analysed to capture subjective wellbeing.  For further 
information on the phenotype definitions and GWAS 
methods for all traits, see supplementary table S2. 
All phenotype scores were z scored apart from blood 
pressure.”39
Explanation
As in STROBE,26 presenting critical elements of study 
design early in the article allows readers to orient 
themselves on the study basics. Authors should clarify 
whether the MR study used individual level participant 
data or SNP level summary data, and whether it uses 
a one sample or two sample MR design. In a two 
sample MR study, one stage can use summary data and 
another stage can use individual level data. Some MR 
studies draw on multiple sources of data (eg, different 
sources for the ascertainment of the association 
between the genetic variant and exposure, and for the 
association between the genetic variant and outcome). 
Furthermore, sources of data could be from meta-
analyses of multiple samples. The general design and 
data sources should therefore be made clear.
We recommend a table to provide clear 
documentation of the sources of genetic-variant 
level information for the MR study (see table 4). For 
example, the genetic variants used to estimate the 
exposure could have been ascertained in one study, 
but the effect size (or weight) of these genetic variants 
on the exposure taken from a separate study. If so, we 
recommend reporting both sources of information. The 
table should be expanded as required. For example, 
if different MR studies with different outcomes are 
added to the study, then authors should add additional 
columns to the table. If additional exposures are 
studied, then additional rows can be added.
If data were extracted from pre-existing studies, 
describe how the data were obtained. If data are publicly 
available, provide a hyperlink to the data source, where 
possible. If using summary level data, ensure that all of 
these details are traceable and allow for a qualitative 
assessment of data sources’ heterogeneity. For each 
data source contributing to the analysis, describe the 
following factors in items 4a to 4e.
Setting (item 4a)
Describe the study design and the underlying 
population, if possible. Describe the setting, locations, 
and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection, when 
available.
Examples
“This study comprised a meta-analysis of directly 
genotyped and imputed SNPs from 21 cohorts 
totalling 42,024 individuals (Table 1). An expanded 
description of the participating studies is provided in 
the Text S2.”40
“A total of 23 cohorts with genome wide genotyping 
and fracture data were recruited globally through 
the GEnetic Factors for OSteoporosis consortium 
(GEFOS; http://www.gefos.org/). These cohorts were 
predominantly of European descent and from Europe 
(n=13), North America (n=8), Australia (n=1), and east 
Asia (n=1; tables S1A and S2A), and included 20 439 
fracture cases and 78 843 controls.”41
Explanation
Readers need information on the population(s) 
studied, setting, and locations to assess the context and 
generalisability of the study results. Exposures such 
as environmental factors and therapies can change 
over time. Also, study methods could evolve over 
time. Knowing when a study took place and over what 
period participants were recruited and followed up 
puts the study in historical context, which is essential 
for interpreting results. Where such information has 
Table 4 | Description of GWAS consortiums used for each phenotype. Table reproduced with permission from Wootton et 
al, 201839
Variable First author (year) Consortium Sample size Population* Sex*
Subjective wellbeing Okbay25 (2016) SSGAC 298 420 100% European Mixed†
Body mass index Locke26 (2015) GIANT 339 224 95% European 53% female
Waist to hip ratio Shungin27 (2015) GIANT 210 088 100% European 56% female
Waist circumference Shungin27 (2015) GIANT 232 101 100% European 55% female
Body fat percentage Lu28 (2016) Not available 100 716 89% European 48% female
HDL cholesterol Willer29 (2013) GLGC 92 860 100% European Mixed†
LDL cholesterol Willer29 (2013) GLGC 83 198 100% European Mixed†
Total cholesterol Willer29 (2013) GLGC 92 260 100% European Mixed†
Coronary artery disease Nikpay30 (2015) CARDIoGRAMplusC4D Cases=60 801; 
controls=123 504
77% European Mixed†
Myocardial infarction Nikpay30 (2015) CARDIoGRAMplusC4D Cases=43 676; 
controls=128 199
Mixed† Mixed†
Diastolic blood pressure Wain31 (2017) Not available 150 134 100% European 60% female
Systolic blood pressure Wain31 (2017) Not available 150 134 100% European 60% female
SSGAC=Social Science Genetics Association Consortium; GLGC=Global Lipids Genetics Consortium; GIANT=Genetic Investigation of Anthropometric Traits 
consortium; HDL=high density lipoprotein; LDL=low density lipoprotein; GWAS=genome wide association study. 
*If not reported, percentage sex and European ancestry were calculated from contributing cohort data in the supplementary materials. All GWAS had 
similar sex ratios and ancestries included. The largest difference was between the consortiums for coronary artery disease and subjective wellbeing, 
which used 77% and 100% individuals of European ancestry, respectively. If two populations differ, two sample mendelian randomisation can still be 
used to test for a causal effect, but the magnitude of the effect might not be as precise.32
†Information on the sex ratios and ancestry proportions for the whole sample were not reported or not possible to calculate in the CARDIoGRAMplusC4D, 
GLGC, and SSGAC consortiums.
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been described in previous publications, unambiguous 
reference to these is likely to be sufficient. Providing 
a description of the ancestry of the participants will 
help understand potential sources of heterogeneity 
and generalisability of results. If summary level data 
from existing studies are used, ensure that details are 
traceable to allow for a qualitative assessment of any 
heterogeneity of settings across data sources.
Participants (item 4b)
Give the eligibility criteria, and the sources and 
methods of selection of participants. Report the 
sample size, and whether any power or sample size 
calculations were carried out before the main analysis.
Example 
“The UK Biobank recruited more than 500 000 people 
aged 37-73 years (99.5% were between 40 and 69 
years) from across the country in 2006-10. Participants 
provided a range of information via questionnaires 
and interviews (such as demographics, health status, 
and lifestyle); anthropometric measurements, blood 
pressure readings, and blood, urine and saliva samples 
were taken for future analysis. This has been described 
in more detail elsewhere. We used 120 286 participants 
of white British descent from the initial UK Biobank 
dataset, of whom 119 669 had valid genetic data and 
both BMI and height measures available. We did not 
include other ethnic groups, because individually 
they were underpowered.”42 (Further examples are 
available in web appendix 2.)
Explanation
Detailed descriptions of the study participants 
and sampling frame help readers understand the 
applicability of the results. Authors should provide 
all the eligibility criteria, participant sources and 
methods for selecting participants, and methods of 
follow-up where applicable. Method of recruitment 
into the study should likewise be described. Where 
such information has been described in previous 
publications, unambiguous reference to these is likely 
to be sufficient. If summary level data from existing 
studies are used, ensure that details are traceable to 
allow for a qualitative assessment of participants’ 
heterogeneity across data sources.
In case-control studies, the choice of cases and 
controls is crucial to interpreting the results, and the 
method of their selection has major implications for 
study validity. In general, controls should reflect the 
population from which the cases arose.
If sample size or power calculations were conducted 
before the main analysis, this should also be reported 
either with the study design or the statistical methods. 
When planning a study or interpreting the analysis 
results, information about the sample size is essential. 
Power calculations provide information about sample 
sizes needed to obtain appropriate power for desired 
precision of the effect estimate,43 44 and if they are 
performed, they should be performed before the study 
was conducted. Statistical power is best ascertained 
by examination of the 95% confidence intervals of the 
estimates, since they require fewer assumptions than 
pre-experiment power calculations.
Genetic variants (item 4c)
Describe measurement, quality control and selection 
of genetic variants.
Examples
“Genotyping was conducted using the Affymetrix UK 
Biobank Array. Autosomal analysis was restricted to 
up to 13,977,204 high-quality Haplotype Reference 
Consortium imputed variants with a MAF [minor 
allele frequency] >0.05%, minor allele count >5, info 
score >0.3, genotype hard call rate >0.95, and Hardy–
Weinberg P>1×10−6.”45
“Genetic markers for various obesity-related risk 
factors comprised SNPs that were associated with 
the risk factor of interest (P<5×10−8) based on study 
participants with European ancestry. Correlated 
SNPs were excluded based on measures of linkage 
disequilibrium (LD) R2 <0.1 . . . SNPs with ambiguous 
strand codification (A/T or C/G) were replaced by SNPs 
in genetic linkage (R2 >0.8) using the proxy snps R 
package (European populations) (R Project) or were 
removed from the analyses if the minor allele frequency 
was higher than 0.4.”46
Explanation
Providing information on the ascertainment of 
genotypes and their quality control will enable readers 
to assess the quality of the genetic variants used in the 
study. For two sample MR, this information will often 
require referring to supplementary material presented 
in previously published articles.
The methods section should provide a clear 
explanation of the selection and inclusion of specific 
genetic variants in the analysis. This information 
would include a description of genetic variants 
allocated to the exposure of interest and in the case 
of reverse MR, the genetic variants allocated to the 
outcome. For each variant, the rsID or base position 
and chromosome should be disclosed, along with 
clear reasoning for the variant choice and the reference 
panel used. The reasoning could include the evidence 
of association with the exposure or outcome of interest 
or the characteristics that qualify the specific variant 
to be used, such as linkage disequilibrium in the 
case of proxy use. The inclusion of variants in high 
linkage disequilibrium might not contribute additional 
information in estimating the causal effect, and could 
even lead to biased estimates of standard errors if this 
correlation structure is not accounted for.47 Authors 
should define the threshold used to select independent 
variants (eg, r2), the reference panel, and the population 
under investigation. However, there are cases in 
which variants (although in linkage disequilibrium) 
from a specific gene region with biological relevance 
regarding the exposure of interest can also be included. 
In this situation, authors should describe the biological 
pathways in which these variants are implicated, the r2 
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threshold for inclusion, and which method was used to 
model the correlation structure.
Studies should also provide estimates of the quality 
control parameters for the SNPs used in analyses. 
This information includes the info score (metric of 
imputation quality), call rate (percentage of individuals 
with called alleles at a particular SNP), and P value 
from the Hardy-Weinberg equilibrium test (which 
could indicate imputation or genotyping problems, 
population stratification, or non-random mating).
Further information is required to chart the 
management of genetic variants and harmonisation of 
datasets in two sample MR analysis. This information 
includes the conditions used to identify proxy variants 
in the absence of the same variant being available in 
both datasets (eg, linkage disequilibrium threshold), the 
presence or absence and handling of strand alignment, 
and orientation of effect and non-effect alleles. Other 
aspects, such as temporal stability of association, 
population specificity, or biological plausability, could 
help understand the selected genetic variants’ validity 
to be used as instrumental variables.
Assessment and diagnostic criteria for diseases 
(item 4d)
For each exposure, outcome, and other relevant 
variables, describe methods of assessment and 
diagnostic criteria for diseases.
Example—continuous exposure or outcome
“Outcomes of the study were WHR [waist-to-hip ratio] 
(stages 1 and 2b), hip and waist circumference (stage 
2a), compartmental body fat masses (stage 3) . . . WHR 
was defined as the ratio of the circumference of the 
waist to that of the hip, both of which were estimated 
in centimeters using a Seca 200-cm tape measure . . 
. Compartmental fat masses were measured in grams 
by DEXA, a whole-body, low-intensity x-ray scan that 
precisely quantifies fat mass in different body regions 
. . . using a Lunar Prodigy advanced fan beam scanner 
(GE Healthcare). Participants were scanned by trained 
operators using standard imaging and positioning 
protocols. All images were manually processed by one 
trained researcher, who corrected DEXA demarcations 
according to a standardised procedure.”48 (Further 
examples are available in web appendix 2.)
Explanation
This section provides details on the choice and 
definition of key exposures, outcomes, and confounders 
used in the analyses. Where several outcomes or 
hypothesis-free approaches are used, this information 
should be clearly indicated, together with any method 
that accounts for multiple testing. This section will 
ideally include definitions used in each study (for 
meta-analyses of different studies) or provide a brief 
summary with a clear reference if this has previously 
been described for the study sample. Readers can 
then consider the case definition’s sensitivity and 
specificity, and assess the relevance for their question 
or the generalisability to their population of interest.
Ethical approval and informed consent (item 4e)
Provide details of ethics committee approval and 
participant informed consent, if relevant.
Example
“Informed consent was obtained from all participants, 
and study protocols were approved by the local, 
regional, or institutional ethics committees.”49
Explanation 
All investigators must ensure that the planning, 
conduct, and reporting of human research are in 
accordance with the Helsinki Declaration as revised 
in 2013.50 Authors need to provide information on the 
approval from the responsible ethics committee and 
acquisition of the informed consent. This information 
should also be made available if the data were obtained 
from publicly available sources or previously conducted 
studies. Authors should make sure that their study falls 
into the scope of the original ethics committee approval 
and does not violate the original agreement.
Assumptions (item 5)
Explicitly state the three core instrumental variable 
assumptions for the main analysis (relevance, 
independence, and exclusion restriction) as well as 
assumptions for any additional or sensitivity analysis.
Examples
“As in any Mendelian randomisation analysis, several 
assumptions were made, including that the genetic 
instruments were associated with the risk factor of 
interest, were independent of potential confounders, 
and could only affect the outcome through the risk 
factor and not through alternative pathways (that is, 
through pleiotropy).”51
“Additionally, the slope of MR-Egger regression 
can provide pleiotropy-corrected causal estimates… 
An important condition of approach is that a  SNP’s 
association with the exposure variable must be 
independent of its direct effects upon the outcome 
(previously described as the InSIDE assumption).”52
Explanation
Explicitly stating the three core instrumental variable 
assumptions, ideally in the methods sections, can help 
readers to understand the underlying premises of the 
MR method, and to allow them to judge their validity. 
Ideally, the assumptions would be stated in the text 
using intuitive language specific to the study setting 
and what they imply in the context of the question being 
asked. Articulating the assumptions also motivates 
sensitivity analyses and other additional analyses 
used to assess the assumptions or the robustness of 
conclusions to their violations.
When instrumental variable estimation is used to 
obtain effect estimates, a fourth assumption should 
then be stated: typically, an assumption of effect 
homogeneity53 or monotonicity.54 In many MR studies, 
other methods are used to augment traditional 
instrumental variables estimators (eg, two stage least 
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squares or Wald estimators), and their assumptions 
should also be stated. For example, MR Egger 
regression55 or weighted median56 57 are often used as a 
supplementary analyses to obtain the estimates when 
multiple genetic variants are included. Box 2, figure 1, 
and box 3 give more details on instrumental variable 
assumptions, common violations, and assessment.
Statistical methods: main analysis (item 6)
Describe statistical methods and statistics used.
Quantitative variables (item 6a)
Describe how quantitative variables were handled in 
the analyses (that is, scale, units, model).
Example
“The effect size for each meta-analysis is reported 
in the main results as the effect of a one-standard-
deviation (1-SD) change in natural-log-transformed 
25OHD [25-hydroxyvitamin D] level, since this metric 
is more interpretable than an arbitrary difference . . . 
In order to provide a better clinical interpretation of a 
1-SD change in natural-log-transformed 25OHD level, 
we selected three different clinically relevant 25OHD 
thresholds for vitamin D status (<25 nmol/l for vitamin 
D deficiency, <50 nmol/l for vitamin D insufficiency, 
and >75 nmol/l for vitamin D sufficiency).”78
Explanation
Any transformations made in the quantitative variables 
(that is, exposure, outcome, or relevant covariates) 
should be explicitly mentioned, because they affect 
both interpretation of results and their comparability 
with other studies. Describing biological knowledge or 
previous evidence can help justify chosen groupings. 
When possible, authors should also back-transform 
estimates to report the units of measurement in 
common terms to enable future replication of findings. 
For example, if the effect size is reported in standard 
deviation change, we suggest reporting the magnitude 
of the standard deviation for clarification.
Genetic variants (item 6b)
Describe how genetic variants were handled in the 
analyses and, if applicable, how their weights were 
selected.
Example
“We created an allele score from 97 genetic variants 
previously found to be associated with BMI [body mass 
index], in a recent GWAS [genome wide association 
study] meta-analysis by the GIANT consortium. 
The score was calculated as a sum of the number of 
BMI-increasing alleles, weighted by the effect size 
as reported in the GIANT GWAS (reported as a SD 
[standard deviation] change of BMI per dosage increase 
such that a higher allele score corresponds to a higher 
BMI, and was standardised to have a mean of zero and 
SD of 1).”79
Explanation
An allele score (also sometimes referred to as genetic 
risk score, polygenic risk scores, or genetic prediction 
scores) is a variable that summarises multiple genetic 
variants in one measure. When many variants are 
included in the score, bias and coverage probabilities 
of the instrumental variable estimates are improved 
compared with estimates from the two stage least 
Box 2: Instrumental variable (IV) assumptions and mendelian randomisation (MR)
Core IV estimation assumptions and additional assumptions
Most MR studies rely on three core IV assumptions (relevance, independence, and exclusion restriction; fig 1, 
box 3) to carry out testing for causal effects of the exposure on the outcome.16 Estimating effect sizes through the 
instrumental variable approach imposes a fourth assumption, usually homogeneity of effects of the exposure on the 
outcome.16 58-60 The homogeneity assumption can also be replaced by imposing a monotonicity assumption that an 
increase in the number of risk alleles does not lower the likelihood of exposure for any individuals, typically leading to 
estimating an effect in a subgroup of the study population.61
Violations
The exclusion restriction is sometimes also referred to as an assumption of no horizontal pleiotropy (box 3), but it can 
be violated in several other ways (eg, by gene-exposure interaction, by having some form of time varying exposures, 
by measurement error in the exposure that is related to the instrument or by a multi-component exposure).59 
Concerns about violations of the independence assumption usually focus on confounding by ancestry (or population 
stratification). However, it can also be violated by various forms of selection or collider bias, by dynastic effects, or 
by assortative mating.62-64 When multiple variants are used in the analysis, these assumptions pertain to each of the 
variants. Other methods can relax these assumptions, as described below.
Assumptions for additional analyses
In many MR studies, instrumental variable methods have been extended in several ways. For example, when 
multiple genetic variants are used, MR Egger regression,55 weighted median,56 or weighted mode57 are often used as 
supplementary estimators. MR Egger regression relaxes the exclusion restriction assumption but imposes an InSIDE 
assumption that the size of the direct effects of the genetic variants on the outcome that do not operate through the 
exposure are independent of the size of the genetic variants’ effects on the exposure. Additionally, the two sample 
MR approach assumes that the association between the genetic variants and the exposure is the same in the two 
samples, which might not hold if samples are selected from different subpopulations (eg, by sex, age, ethnicity).
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squares approach.80 Authors should explicitly define 
the criteria for selecting variants included in the allele 
score and whether these criteria are based on external 
data. An allele score could be weighted or unweighted. 
If weighted, author should clarify whether the weights 
are derived from the data under analysis or from 
an independent data source. Authors should also 
report which genetic model of inheritance is implied 
in the calculation of genetic variant-exposure and 
variant-outcome associations (that is, additive or 
multiplicative). If the weights were derived from the 
same sample (eg, in a one sample MR), authors should 
report any efforts to mitigate potential overfitting, 
typically using methods such as the cross validation or 
jackknife approaches.
Mendelian randomisation estimator (item 6c)
Describe the MR estimator (eg, two stage least squares, 
Wald ratio) and related statistics. Detail the included 
covariates and, for two sample MR studies, whether 
the same covariate set was used for adjustment in the 
two samples.
Example
“Genetic associations with all exposures were taken 
from a large meta-analysis of GWAS, conducted in 
adults (n=108,557; mean age, 50.6 years; ~53% men) 
of European ancestry, without diabetes, adjusted for 
age, sex, study site and geographic covariates using an 
additive genetic model . . . Genetic associations with 
MI [myocardial infarction], angina and heart failure 
were obtained using logistic regression controlling 
for age, assay array and 10 principal components in 
sex-specific analysis and additionally adjusted for 
sex in the overall analysis, as the adjustment in our 
previous MR study in the UK Biobank . . . Specifically, 
we obtained SNP-specific Wald estimates (quotient of 
genetic association on outcome and genetic association 
on insulin) and then meta-analysed them using inverse 
variance weighting (IVW) with multiplicative random 
effects.”81
Explanation
The authors should present all the analytical details on 
the calculation of the instrumental variable estimator. 
Further clarification on estimating the associated 
standard errors should also be provided (that is, if 
this estimator is based on a normal approximation, 
bootstrapping, or other approaches). Covariates used 
in the MR analysis should be detailed. For a two sample 
analysis, authors should state the covariates used to 
estimate the genetic variant-exposure and genetic 
variant-outcome associations to assess any differences 
in the use of covariates between the two associations, 
which could lead to bias.
Missing data (item 6d)
Explain how missing data were addressed.
Example
“We conduct our analyses in a Bayesian framework as 
this lends itself naturally to data imputation. We first 
introduce a Bayesian complete-case analysis method 
and then 4 methods for imputing data under the missing-
at-random assumption that can be incorporated into 
the Bayesian model to include subjects with missing 
data . . . We use cross-sectional baseline data on 3,693 
participants who have complete or partial data for 
C-reactive protein, fibrinogen, and the 3 SNPs. There 
is missingness in 2.1% of participants for C-reactive 
protein, 2.4% for fibrinogen, 10.8% for rs1205, 1.9% 
for rs1130864, and 2.6% for rs1800947.”82
Explanation
The inclusion of multiple variants with missing data 
in the estimation of causal effects could decrease 
precision. Authors should present the percentage of 
missing data as well as whether any imputation was 
performed. If imputation was performed the authors 
should report details of the imputation panel and 
method of imputation.
Multiple testing (item 6e)
If applicable, indicate how multiple testing was 
addressed.
Example
“The significance threshold for all cancer risk and 








Fig 1 | Canonical causal diagram illustrating the 
assumptions of instrumental variable (IV) analyses. 
Genetic variant G is used as an instrumental variable 
(proxy) for exposure X to assess its causal effect on 
outcome Y. IV assumptions include: I. Relevance: genetic 
variant G is associated with the exposure of interest X; II. 
Independence: genetic variant G shares no unmeasured 
cause with outcome Y; III. Exclusion restriction: genetic 
variant G does not affect outcome Y except through 
its potential effect on the exposure of interest X. Solid 
arrows=causal effects; dashed arrows=causal effects 
that are specifically prohibited by the IV assumptions. 
Note that other causal diagrams can be drawn that 
satisfy the IV assumptions (eg, genetic variant G does 
not have to directly cause exposure X); likewise, other 
pathways not drawn might violate the IV assumptions 
(eg, selection biases can also lead to violation of the 
independence assumption)
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mortality) require correcting 0.05 by 12 tests) . . . 
Given 6 individual cancers were considered, we set a 
significance threshold of 0.004/36=0.0001.”83
Explanation
In an MR analysis that involves multiple exposures or 
multiple outcomes, authors should state whether and 
how they accounted for multiple testing and provide 
justification. They should state whether the correction 
was for the total number of statistically independent 
exposures or outcomes for all exposures and 
outcomes. Such a correction could involve reporting 
false discovery rates, Bonferroni correction, or other 
techniques, as outlined in the above example.
Assessment of assumptions (item 7)
Describe any methods or previous knowledge used to 
assess the assumptions or justify their validity.
Examples
“Mendelian randomisation was implemented using 
the two stage least squares method in the R package 
ivpack. We included age and sex as covariates. To 
assess the risk of weak instrument bias, we used 
F tests to determine the strength of association in 
the first stage regressions between allele score and 
exposure . . . We used confounding bias plots to assess 
relative bias in the instrumental variable estimate 
compared with standard multivariable regression . . . 
Box 3: Assessment of assumptions of mendelian randomisation and sensitivity analyses
Relevance
For the relevance assumption, authors should report how they measured instrument strength. Reporting the F statistic, if individual level data are 
available, provides several advantages for understanding the risk of weak instrument bias.65 The F statistic can also be approximated using summary 
level data. If the proposed instrument strength is low, reporting should include whether approaches that are robust to weak instruments have been 
used.
Independence
The independence assumption cannot be directly verified, but it can be partially assessed in many research settings. Negative control outcomes 
or negative control populations can sometimes evaluate the reasonableness of the assumption.66 Reporting associations between measured 
covariates that might confound the variant-outcome association can also prove helpful, particularly if scaled by instrument strength67 68 or presented 
alongside a related bias analytical approach.69
Exclusion restriction
For the exclusion restriction assumption, MR Egger regression55 can be used to detect certain versions of pleiotropy and therefore provide evidence of 
certain violations of the exclusion restriction. However, the approach depends on an additional assumption (described above) and requires multiple 
independent variants. Additional approaches to test the exclusion restriction include weighted median56 and mode.57 The use of negative control 
outcomes or negative control populations might also allow evaluation of this assumption.70 The use of known biological effects of a SNP can also be 
leveraged to decrease the probability of violation of this assumption.
Homogeneity
The homogeneity assumption requires that the exposure has the same effects in everyone, which is not directly verifiable. One possibility for 
supporting its validity is to determine whether the effect estimate, or even the genetic variants’ effects on the exposure, is the same across 
subpopulations.67 71 Authors can perform stratified or adjusted analyses to relax this assumption if effects with meaningful differences are estimated 
in different subpopulations.72 Furthermore, a global exploration of the homogeneity assumption can examine any differences in variance of a 
continuous outcome across the genetic instrument; the extent of such differences provides evidence as to extent of violation of the homogeneity 
assumption.
Joint falsification strategies
Some falsification strategies assess assumptions jointly. When using multiple genetic variants as proposed instruments, it is possible to test 
whether heterogeneity exists across the separate effect estimates (see Test for difference, table 2). Although this test is often interpreted as an 
assessment of the exclusion restriction, it is jointly testing the exclusion restriction, independence, and homogeneity assumptions. Another 
relatively straightforward joint test of all assumptions comes from comparing the effect estimate with that obtained by use of a more traditional 
confounding-adjustment approach.73 Assuming that the traditional approach is biased owing to unmeasured confounding, and that the direction of 
that confounding is suspected, the examination of whether the MR effect estimate aligns with the suspected direction of confounding can support 
the joint validity of the assumptions underlying the MR effect estimate.
Sensitivity analyses
Because several of the estimators using multiple genetic variants rely on different versions of relaxing or adapting the instrumental variable 
assumptions (eg, MR Egger, median based, or modal based estimators), a comparison of estimates obtained using each of these approaches 
can help understand the sensitivity of effect estimates to the non-overlapping assumptions of each.74 Researchers might also compare MR effect 
estimates with non-MR estimates, depending on the assumptions underlying alternative methods. Independent replication of MR findings in an 
independent dataset or with a different study design (eg, one sample v two sample MR) is typically advocated to assess the findings’ robustness. 
Many of the traditional bias analytical techniques in epidemiology can be adapted for MR readily, including the calculations from formulas for 
understanding the magnitude and direction of confounding bias59 67-69 75 or for violations of the exclusion restriction.5976 When selection bias is 
a concern, researchers also frequently conduct simulations to understand the plausible size and direction of bias.64 Simulations might also help 
understand the plausible size and direction of bias induced by assortative mating,62 dynastic effects,9 63 and time varying effects,77 if deemed 
relevant.
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To investigate the degree of bias in the initial causal 
estimates due to pleiotropic effects, we used two 
sensitivity analyses (mendelian randomisation-Egger 
and weighted median mendelian randomisation) . . . 
Mendelian randomisation-Egger and weighted median 
methods were implemented using the R package 
TwoSampleMR.”84
“There are reasons for considering MR analysis of 
a protein drug target to be a distinct category of MR 
analysis . . . Aside from mRNA expression, differences 
in protein expression or function are the most proximal 
consequence of natural genetic variation. This has two 
consequences: frequently, variants located in and 
around the encoding gene can be identified with a very 
substantial effect on protein expression in comparison 
to other traits; moreover such instruments may also be 
less prone to violating the ‘no horizontal pleiotropy’ 
assumption than variants located elsewhere in the 
genome . . . In the case of MR analysis of proteins, 
Crick’s ‘Central Dogma’ imposes an order on the 
direction of information flow from gene to mRNA to 
encoded protein, which does not extend beyond this 
to other biological traits that lie more distally in the 
causal chain that connects genetic variation to disease 
risk. Finally, cis-MR of a protein risk factor greatly 
reduces the risk of reverse causation, because Crick’s 
dogma indicates that the pathway gene → encoded 
protein → disease would always be favoured over the 
pathway gene → disease → encoded protein, especially 
given that the gene → encoded protein association is 
typically derived from population-based (disease-free) 
samples. Thus, from an MR perspective, proteins are 
in a privileged position compared with other categories 
of risk factor and the use of cis-MR represents an 
optimal approach to instrument their causal effect for 
disease.”85
Explanation
For each of the assumptions underlying an MR 
analysis, authors should report any methods used 
to assess the assumptions or justify their validity. 
Generally, the subject related background can be used 
to support the reasonableness of each assumption. 
While many assumptions cannot be verified, there 
are methods available to attempt to falsify them. In 
line with the relevance assumption, the authors can 
report how they assessed instrument strength. If 
the proposed instrument strength is low, reporting 
might include whether approaches that are robust to 
weak instruments have been used. Although many 
possible methods are available, some are usable only 
in certain settings (eg, for dichotomous exposures). 
Box 3 describes some of the more common and useful 
approaches, and table 5 lists the commonly used 
statistics used when examining assumptions and 
performing sensitivity analyses. The first three core 
assumptions pertain to any MR analysis with a single 
instrument; the additional assumptions are needed 
for instrumental variable estimation. Exclusion 
restriction is relaxed in sensitivity analyses such as MR 
Egger regression. These assessments and sensitivity 
analyses do not represent an exhaustive list of possible 
strategies, and not all sensitivity analyses are relevant 
to all MR analyses. For example, F statistics are 
principally relevant for instrumental variable analyses, 
because they are approximately equivalent to variance 
explained in two sample MR approaches based on 
genome wide association study (GWAS) output. 
Associations with measured covariates (eg, age, sex, 
and race or ethnic origin) and effect estimates across 
subpopulations can be reported with one sample MR 
studies, but generally not with two sample MR studies, 
however, GWAS summary statistics are increasingly 
available for sex and ancestry specific analyses. More 
comprehensive reviews are provided by Glymour et 
al73 and Labrecque and Swanson.86
Sensitivity analyses and additional analyses (item 8)
Describe any sensitivity analyses or additional 
analyses performed (eg, comparison of effect estimates 
from different approaches, independent replication, 
bias analytical techniques, validation of instruments, 
and simulations).
Examples
“Confounding: We used confounding bias plots to 
assess relative bias in the instrumental variable 
estimate compared with standard multivariable 
regression. Such analyses are designed to quantify the 
bias present in a mendelian randomisation analysis 
in a manner analogous to examining the effect of 
adjusting or not adjusting for a potential confounder 
in a standard regression analysis. Additionally, in 
supplementary analyses we included suspected 
confounding factors as covariates (see supplementary 
table 4). The confounding variables considered were 
the first 10 genetic principal components, Townsend 
deprivation index, birth weight, breast fed, and place 
of birth (northing and easting coordinates).
“Horizontal (genetic) pleiotropy: To investigate the 
degree of bias in the initial causal estimates due to 
pleiotropic effects, we used two sensitivity analyses 
(mendelian randomisation-Egger and weighted median 
mendelian randomisation). Mendelian randomisation-
Egger is not valid for studies in which the instrumental 
variable-exposure and instrumental variable-outcome 
associations are calculated in the same sample (as was 
done for the main analyses in this study). Therefore, 
we ran the mendelian randomisation-Egger as a split 
sample analysis, by randomly splitting the sample in 
half (groups A and B). The supplementary data table 
shows the associations of the variants and time spent in 
education and refractive error for each group. Mendelian 
randomisation-Egger and weighted median methods 
were implemented using the R package TwoSampleMR 
(https://github.com/MRCIEU/TwoSampleMR).
“Measurement error: To ensure the association 
between time spent in education and myopia was 
not an artefact of the non-normal distribution of 
the variable for age when full time education was 
completed, we used two alternative methods to recode 
time spent in education: dichotomisation into age more 
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than 16 years when education was completed and age 
16 years or less when education was completed; and 
excluding those who attended college or university. 
We compared the results with the original analyses 
using the continuous variable for age when full time 
education was completed.”87
“Tests of association for individual genetic 
variants were complemented with gene-based tests of 
association and S-PrediXcan analysis. The latter was 
used to identify genes with differential expression 
levels in cannabis users versus nonusers. We further 
estimated the genetic correlation of lifetime cannabis 
use with other traits, including use of other substances 
and mental health traits, such as schizophrenia. Lastly, 
we performed bidirectional two-sample Mendelian 
randomization analysis to examine whether there was 
evidence for a causal relationship from cannabis use to 
schizophrenia risk, and from liability to schizophrenia 
to cannabis use.”88 (Further examples are available in 
web appendix 2.)
Explanation
Sensitivity analyses can test the robustness of effect 
estimates to plausible violations of the underlying 
assumptions and help understand the plausible 
size or direction of bias. Authors should report on 
any such sensitivity analyses performed. Some 
common strategies are described in box 3, and further 
information is available elsewhere.55 74 86
Software and pre-registration (item 9)
Statistical software (item 9a)
Name statistical software and package(s), including 
version and setting used.
Example
“We performed the analysis by using Stata version 14 
(StataCorp LP) and R version 3.4.3 (The R Foundation 
for Statistical Computing). We used the mrrobust 
package for Stata and the TwoSample MR package for 
R to facilitate MR analyses.”89
Explanation 
Statistical methods and software should ideally 
be described with enough detail to enable a 
knowledgeable user with access to the original data to 
verify the reported results. It is preferable to provide 
the statistical code used in an online repository.
Pre-registration (item 9b)
State whether the study protocol and details were pre-
registered (as well as when and where).
Explanation
Authors should report if a study was pre-registered and 
provide a link to the study protocol. Examples of pre-
registration in MR are rare at present, partly because 
it poses challenges for secondary data analysis. 
Potential solutions that protect against researcher 
bias have been proposed: “The pre-registration can be 
achieved by pre-specifying the rationale, hypotheses, 
methods, and analysis plans, and submitting these 
to either a third-party registry (e.g., the Open Science 
Framework [OSF]; https://osf.io/), or a journal in the 
form of a Registered Report.”90 Wider adoption of these 
methods should increase the accuracy, transparency, 
and robustness of MR studies.
Results
Descriptive data (item 10)
Number of participants (item 10a) 
Report the numbers of individuals at each stage of 
included studies and reasons for exclusion. Consider 
the use of a flow diagram.
Example
“UK Biobank recruited 502 664 participants aged 40 
to 69 years through 22 assessment centres across the 
UK . . . All participants completed sociodemographic 
questionnaires, which included questions on past 
educational and professional qualifications. In the 
latter stages of recruitment, an ophthalmic assessment 
was introduced, and this was completed by 
approximately 23% of participants . . . In total, 69 798 
participants had valid education, refractive error, and 
genetic data available (fig 1).”87
Explanation
Information on study participants will help readers 
understand the target population and assess the 
validity and generalisability of results. It also provides 
readers with the information needed to replicate the 
study and to assess whether the study is likely to show 
collider bias. If the data sources include individual 
level data, authors should report information on the 
participants in the study. Specifically, authors should 
report the number of individuals at each stage of the 
Table 5 | Most common instrumental variable assumptions in mendelian randomisation and examples of possible assessments or sensitivity analyses
Assumptions Examples of possible assessments
Relevance: genetic variants are associated with the exposure of interest Report F statistic
Independence: genetic variants share no unmeasured cause with the 
outcome
Report the associations of plausible confounders with both the genetic variant(s) and the outcome; 
how population stratification has been taken into account (e.g. through principal component 
adjustment); and unmeasured confounding sensitivity metrics for the variant-outcome association59 
68 69 75
Exclusion restriction: genetic variants do not affect the outcome except 
through their potential effect on the exposure of interest
Report results from MR Egger regression slope estimate as well as the intercept and its 95% 
confidence intervals; and results using negative control outcomes or negative control populations
Homogeneity (two stage least squares): there is a constant causal effect 
of the exposure of interest on the outcome
Report the instrumental variable effect estimate for different measurable subpopulations (eg, stratified 
by age, race or ethnic origin, sex, or socioeconomic status); for continuous outcomes, report on 
variance by level of instrument72
InSIDE (MR Egger): associations of genetic variants with the exposure 
variable must be independent of its direct effects on the outcome
Also report the effect estimates from other estimators that do not require this assumption (eg, median 
and modal based tests).
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study and the reasons why individuals were excluded 
from further study. Examples of such reasons include 
loss to follow-up, removal for lack of data, and quality 
control. Including a STROBE26 flowchart for inclusion 
into the study can quickly provide information about 
how the study sample was selected. Where possible, 
report missing values for variables.
Summary statistics (item 10b)
Report summary statistics for phenotypic exposure(s), 
outcome(s), and other relevant variables (eg, means, 
standard deviations, proportions).
Example
“The UK Biobank sample comprised 53.7% women 
(table 1), and the median age at recruitment was 58.0 
years (interquartile range 51.0-63.0). The distribution 
of adiposity [exposure] and smoking behaviour 
[outcome] variables in the UK Biobank sample are 
described in table 1 and table 2 [table 6 and table 7]. 
As observed in previous studies, current smokers had 
a lower body mass index than never smokers (−0.22 
(95% confidence interval −0.27 to −0.16)). Conversely, 
former smokers had a higher body mass index than 
current smokers (1.04 (0.98 to 1.09)).”51
Explanation
Information on the distribution of the exposure, outcomes, 
and other variables helps judge the comparability of 
groups and generalisability of the findings. Distributions 
of continuous variables are easily summarised by mean 
and standard deviation, or by median and percentile 
range (eg, 25th and 75th percentiles) in case of 
asymmetrical distribution. Numbers and percentages 
best describe categorical variables. Readers can assess 
group differences better if the descriptive statistics 
are provided for each category separately. Statistical 
inference regarding differences between groups should 
be reserved for the main analysis.26
In cohort studies in which the outcome is an event, 
authors should report both the number of events and, 
if appropriate, the event rate (eg, number of events per 
person year). A summary measure of follow-up time—
such as mean, median, or total follow-up—is also 
important to understand the period over which events 
were recorded.
For a time varying outcome, for which time-to-event 
data are available, the summary measures should be 
presented over time; a figure could help communicate 
this. In case-control studies, the summary measures 
are typically presented separately for cases and 
controls. A table of continuous exposures or outcomes 
by categories might also be helpful.26
Heterogeneity assessment (item 10c)
If the data sources include meta-analyses of previous 
studies, provide the assessments of heterogeneity 
across these studies.
Example
Table 8 demonstrates the I2 test statistic, allowing 
for an assessment of heterogeneity of the effect of the 
genetic variants on the outcome across studies. 
Explanation
Evidence on the consistency of the genetic variant’s 
association with the exposure or outcome helps to 
understand the degree of heterogeneity of effects. If 
the estimation is based on a meta-analysis, the number 
of included studies will also help determine if tests 
for heterogeneity are properly powered to detect its 
presence. Presenting 95% confidence intervals along 
with the I2 statistic is recommended.91 92
Two sample mendelian randomisation (item 10d)
For two sample MR, authors should (1) provide 
justification of the similarity of the genetic variant-
exposure associations between the exposure and 
outcome samples, and (2) provide information on the 
number of individuals who were in both samples for 
the exposure and for the outcome.
Example 1
“The genetic variants used for MR were obtained 
from a GWAS of gallstones conducted in Europeans. 
A comparison between European and Indian 
populations with respect to allele frequencies, risk of 
developing gallstones and gallbladder cancer (GBC) for 
the genetic variants was made and results are shown 
in Supplementary Table 1. The allele frequencies 
between the two populations were generally similar, 
although with striking differences for some SNPs (e.g. 
for rs601338, rs1260326, rs174567, rs2469991, 
rs2290846, where the difference in minor allele 
frequency was >15%). The risk for developing 
gallstones and GBC were in broadly the same direction 
for the SNPs in the Indian population (consistently 
increased risk for 80% of SNPs in relation to gallstones 
and 70% SNPs in relation to GBC).”93
Explanation 1
Two sample MR analyses assume that the SNP-
exposure associations are similar in the two samples. 
Fig 2 | Numbers of participants in UK Biobank who passed validation for mendelian 
randomisation study. Figure reproduced with permission from Mountjoy et al, 201887
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For example, the analysis assumes that the two 
samples are drawn from the same underlying 
population. However, characteristics such as ethnic 
origin are not the only relevant factors. Similarity 
of the two samples can also be violated if, for 
example, genetic associations were estimated in pre-
menopausal versus post-menopausal women, or in a 
population based sample versus a high risk sample. 
Where this assumption cannot be made, it should be 
evaluated by comparing the SNPs’ association with 
the exposure and the outcome in the two samples, 
whenever the data are available. If the associations 
are similar in the two samples, heterogeneity in the 
associations of the SNPs with the exposure and the 
outcome is less likely to cause bias. Authors should 
also provide information on the number of individuals 
who were in both samples for the exposure and for the 
outcome.
Example 2
“These genome-wide association study estimates were 
selected from studies that did not include UK Biobank 
participants, so as to avoid participant overlap, and 
therefore, in some cases, the genome-wide association 
study and subsequent instruments differed from the 
genome-wide association study studies used for the 
two-sample mendelian randomisation described 
previously.”89
Explanation 2
If the authors used the same or similar individuals 
to estimate the SNP-exposure and the SNP-outcome 
associations, MR estimates could be biased by a form 
of the winner’s curse,94 95 which occurs when the 
statistically strongest associations—usually using a 
P value threshold—are selected from the discovery 
sample. This bias can be overcome by using entirely 
separate samples to select SNPs and estimate SNP-
outcome associations. The bias is a linear function of 
the number of individuals included in both samples, 
so the consequences of a small amount of overlap may 
not be severe.94
Main results (item 11)
Genetic variant associations (item 11a)
Report the associations between genetic variant and 
exposure, and between genetic variant and outcome, 
preferably on an interpretable scale.
Example
“The BMI allele score created from the 12 BMI-related 
SNPs showed a positive dose-response association 
with BMI (per unit increase 0.14% [0.12%–0.16%], 
p = 6.30×10−62). The BMI allele score was also 
associated with 25(OH)D concentrations (per unit 
increase −0.06% [-0.20% to −0.02%], p=0.004).”40
Explanation
Reporting the association between the genetic variant 
and the exposure is required to evaluate the relevance 
assumption (item 8b). Comparing levels of exposure 
across the genotype distribution can also indicate 
monotonicity and linearity of the genetic effect. 
Reporting on the association between the genetic 
variant and the outcome is useful because it can 
provide an initial indication about the possibility of a 
causal association between the exposure and outcome.
Mendelian randomisation estimates (item 11b)
Report MR estimates of the association between 
exposure and outcome, and the measures of 
uncertainty from the MR analysis, on an interpretable 
scale, such as odds ratio or relative risk per standard 
deviation difference.
Example
“The odds ratio of CAD [coronary artery disease] per 
1-standard deviation increase in genetically predicted 
BMI was 1.49 (95% CI [confidence interval] 1.39 to 
1.60).”96
Table 6 | Sample characteristics of body size parameters by smoking and sex categories in UK Biobank. Data are mean (standard deviation). Table 
reproduced with permission from Carreras-Torres et al, 201851
Body size parameters Total (n=372 791)
Smoking category Sex
Never (n=203 735) Former (n=131 537) Current (n=37 519) Female (n=200 247) Male (n=172 544)
Body mass index 27.4 (4.8) 27.1 (4.7) 28.0 (4.7) 27.0 (4.8) 27.0 (5.1) 27.9 (4.2)
Weight (kg) 78.3 (15.9) 77.0 (15.6) 80.5 (16.0) 78.0 (16.3) 71.5 (13.9) 86.2 (14.3)
Height (cm) 168.8 (9.2) 168.3 (9.3) 169.4 (9.1) 169.5 (9.2) 162.7 (6.2) 175.9 (6.7)
Waist circumference (cm) 90.4 (13.5) 88.8 (13.2) 92.6 (13.6) 91.2 (13.5) 84.6 (12.5) 97.1 (11.3)
Body fat percentage (%) 31.4 (8.5) 31.5 (8.6) 31.7 (8.2) 29.9 (8.6) 36.6 (6.9) 25.3 (5.8)
Table 7 | Sample characteristics of smoking parameters by body mass index and sex categories in UK Biobank ever smokers (current plus former 




















Age started smoking (years) 17.3 (4.2) 17.5 (4.8) 17.6 (4.2) 17.3 (4.2) 17.1 (4.3) 17.8 (4.4) 16.9 (4.0)
No of cigarettes smoked per day
 Ever smokers 18.4 (10.1) 16.6 (10.5) 15.9 (8.6) 18.2 (9.6) 21.1 (11.5) 16.1 (8.2) 20.5 (11.2)
 Current smokers* 15.8 (8.4) 16.8 (11.1) 15.0 (8.2) 15.6 (8.1) 17.3 (9.0) 14.2 (7.3) 17.4 (9.2)
*N=37 519 current smokers.
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Explanation
If the instrumental variable assumptions are not 
apparently falsified and are generally supported, 
or sensitivity analyses are robust to violation of the 
assumptions (item 8b), then estimates from the MR 
analysis can be reported in a meaningful manner, 
preferably on an intuitive scale (eg, relative risk, 
risk difference). However, if the homogeneity and 
monotonicity assumptions do not hold, it might be 
preferable not to report the estimates and outline this 
situation. Instead, the estimation is replaced by testing 
for a non-null effect.
Calculating absolute risk (item 11c)
If relevant, consider translating estimates of relative 
risk into absolute risk for a meaningful time period.
Example
“LDL [low density lipoprotein] cholesterol lowering 
alleles at the NPC1L1 locus were inversely associated 
with coronary artery disease (OR [odds ratio] for 
a genetically predicted 1-mmol/L [38.7-mg/dL] 
reduction in LDL-C of 0.61 [95% CI, 0.42-0.88]; 
P=.008) and directly associated with type 2 diabetes, 
both individually and collectively (OR for a genetically 
predicted 1-mmol/L reduction in LDL-C of 2.42 
[95% CI, 1.70-3.43], P<.001; estimated absolute risk 
difference, 5.3 incident cases per 1000 person-years 
for a 1-mmol/L genetically predicted reduction in 
LDL-C).”97
Explanation
In some instances, the interpretation of estimates 
in terms of absolute risks or risk differences rather 
than relative risk differences might be more clinically 
meaningful, by taking into account the baseline risk. A 
measure of absolute risk can provide an estimate of the 
excess amount of disease that can be attributed to the 
exposure over a particular period, which can then be 
used to estimate the absolute benefit of an intervention 
aimed at reducing levels of the exposure.
Visualisation of results (item 11d)
Consider plots to visualise results (eg, forest plot, 
scatterplot of associations between genetic variants 
and outcome versus associations between genetic 
variants and exposure; see example in fig 3).
Example
Explanation
Plots can be useful for examining potential violations 
of the instrumental variable assumptions, especially 
for the exclusion restriction assumption. Authors 
should report the associations of the exposure and 
outcome with the genetic variants individually, which 
can be presented using a scatterplot or funnel plot.55 
The scatterplot depicts the association of the genetic 
effects on the exposure versus the genetic effects on 
the outcome, with the slope of the line corresponding 
to the estimated causal effect, with an intercept that is 
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8b). A funnel plot, in which causal effect estimates for 
variants are plotted against their precisions, can be 
used to perform a visual inspection for asymmetry, 
which might indicate horizontal pleiotropy.55 Forest 
plots, which plot the causal estimate obtained from 
each genetic variant, allow for a visual inspection of 
heterogeneity around the overall causal estimate.84
Assessment of assumptions (item 12)
Validity of assumptions (item 12a)
Report the assessment of the validity of the 
assumptions.
Example—relevance assumption
“The myopia allele score explained 4.32% (F=3155) 
of the variance in average mean spherical equivalent 
refractive error of participants in UK Biobank and the 
education allele score explained 0.71% (F=464) of 
the variance in time spent in education. We selected 
these genetic variants to use as instrumental variables 
because of their robust association with time spent 
in education and myopia, allowing us to construct 
strong aggregate instrumental variables for making 
mendelian randomisation inferences. The large F 
statistics suggested that these analyses would not be 
affected by weak instrument bias.”87
Example—independence assumption
“In tests of the association between the allele scores 
for time spent in education and myopia with potential 
confounders, there was evidence that the geographical 
coordinate, northing (measured northward distance 
in UK) was negatively associated with time spent 
in education (β=−1.6e-6, 95% confidence interval 
−1.8e-6 to −1.5e-6) and positively with refractive 
error (β=1.2e-6, 9.8e-7 to 1.3e-6). Northing was also 
associated with the time spent in education (P=7e-5) 
and myopia (P=6e-3) allele scores (see supplementary 
table 2). Compared with standard regression, the 
confounding bias plot suggested that inclusion of 
the northing variable in the instrumental variable 
analysis would result in a greater degree of bias for 
the education allele score but not for the myopia allele 
score.”87
Example—exclusion restriction assumption
“MR-Egger, weighted mode, and weighted median 
methods . . . yielded similar causal estimates in 
magnitude and direction, such that increasing time 
spent in education led to a more myopic refractive 
error (by −0.17 to −0.40 dioptres/y), whereas there 
was little evidence that a more myopic refractive 
error led to more time spent in education . . . There 
was little evidence that the Egger intercept deviated 
from zero either for more time in education causing 
refractive error (intercept=0.007, SE=0.006, P=0.2) 
or refractive error causing more time in education 
(intercept=−0.002, SE=0.007, P=0.8), indicating 
that there was little evidence for directional genetic 
pleiotropy.”87
Example—homogeneity
“We observed a J shaped relation between genetically 
predicted BMI and all-cause mortality. The curved 
shape of the relation was more pronounced in UK 
Biobank—with higher risk both in underweight 
participants and in overweight or obese participants. 
The lowest risk for the overall population was at a BMI 
of around 22-23 in the HUNT Study and around 25 in 
UK Biobank.”99
Fig 3 | “Causal relationships of insomnia symptoms. (A) Associations between SNPs associated with frequent 
insomnia symptoms and CAD. Per allele associations with risk plotted against per allele associations with frequent 
insomnia symptom risk (vertical and horizontal black lines around points show 95% confidence intervals (CI) for 
each polymorphism) are shown for three different MR association tests. (B) Forest plot showing the estimates of the 
effect of genetically increased insomnia risk on CAD. Nearest genes are displayed to the right of the plots. Also shown 
for each SNP is the 95% CI (gray line segment) of the estimate and the IVW MR, MR-Egger, and weighted-median 
MR results in red. Sample sizes of each GWAS used in the MR analyses are as follows: frequent insomnia symptoms 
(ncases=129,270; ncontrols=108,352), CAD (ncases=60,801; ncontrols=123,504).”
98 Figure reproduced with permission from 
Lane et al, 201998
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Explanation
Authors should report the results from assessing the 
validity of the instrumental variable assumptions, as 
described under item 7 and box 3. These examples 
illustrate assessments of these assumptions, but do not 
represent an exhaustive list of possible assessments or 
assumptions.
Additional statistics (item 12b)
Report any additional statistics (eg, assessments of 
heterogeneity across genetic variants, such as I2, Q 
statistic, or E value).
Examples
“Cochran’s Q and I2 statistics were calculated to check 
for the presence of heterogeneity (dispersion of SNP 
effects) which can indicate pleiotropy. We found little 
evidence of heterogeneity for the association between 
body mass index and wellbeing (see supplementary 
table S8 for further information).”39
“Chen et al. used a single variant in the ALDH2 
gene to study the effects of alcohol intake on risk of 
hypertension. Among males, the variant-hypertension 
association was an odds ratio of 2.42. The E-value then 
is 4.27. The E-value for the lower limit of the confidence 
interval (1.66) is 2.71. As the analysis was conducted 
in an ethnically homogeneous Asian population, this 
E-value may be large enough to reasonably conclude 
that any residual confounding by ancestry is unlikely 
to explain away the effect.”69
Explanation
Cochran’s Q and I2 statistics can be used to assess 
evidence of heterogeneity of causal effects estimated 
by each of the genetic variants.100 Evidence of 
heterogeneity suggests that there is at least one 
proposed instrument for which at least one of the 
instrumental variable assumptions fails to hold. The E 
value69 can be used to understand the degree to which 
unmeasured confounding might explain findings. A 
large E value could help support that confounding by 
ancestry is unlikely to explain a non-null effect.
Sensitivity analyses and additional analyses  
(item 13)
Sensitivity analyses for main results (item 13a)
Report any sensitivity analyses to assess the robustness 
of the main results to violations of the assumptions.
Example
“The fixed-effect inverse-variance weighted and Egger 
regression estimates suggest an inverse causal effect 
of CRP [C reactive protein] on CAD risk  (table 1). 
However, the corresponding random-effects analyses 
imply that there is no convincing evidence for a causal 
effect. Moreover, the simple median estimate is in 
the opposite direction. This arises because, although 
the strongest genetic variants have negative causal 
estimates, the majority of genetic variants have positive 
causal estimates. The inconsistency of the estimates 
from different methods indicates that the genome-
wide significant variants for CRP are not all valid 
instrumental variables, and that a causal conclusion 
based on these variants would be unreliable.”74
Explanation
Authors should report on, and compare, results 
obtained from different approaches used to assess 
the robustness of conclusions to violation of the 
instrumental variable assumptions, as described 
in section 7 and box 3. If the results from all the 
approaches are largely consistent, author can have 
more confidence in drawing robust conclusions 
regarding the presence and magnitude of a causal 
effect.
Other analyses (item 13b)
Report results from other sensitivity analyses or 
additional analyses.
Example—independent replication
“The associations of genetically predicted body mass 
index and waist circumference with risk of being 
a smoker were replicated in the TAG [Tobacco and 
Genetics consortium] data (1.19 (1.06 to 1.33) and 
1.32 (1.15 to 1.52), respectively.”51
Example —validation of instruments
“The MR-PRESSO method identified one outlier SNP 
for heart failure, six outlier SNPs for coronary artery 
disease, and 11 outlier SNPs for arterial hypertension. 
Outlier-correction did not materially change the OR 
estimates for heart failure (1.13; 95% CI 1.08–1.17), 
coronary artery disease (1.08; 95% CI 1.06–1.10), 
or arterial hypertension (1.10; 95% CI 1.08–1.12). 
No outlier SNPs were identified in the MR-PRESSO 
analysis of the other outcomes.”101
Example—simulations
“Figure 2 shows that TSLS [two-stage least squares 
regression methods] is positively biased when there 
is positive cross-trait assortative mating on X and Y. 
The bias increased proportionally with increasing the 
degree of assortment. However, both TSLS (2) (i.e., 
adjusting for parent’s allele scores) and TSLS (3) (i.e., 
jointly modelling individual’s and parental effects, 
using nontransmitted allele scores as instruments 
of parental phenotype) were unbiased with false 
discovery rates close to 5%.”62
Explanation
Results of sensitivity analyses or additional analyses, 
such as independent replication, validation of 
instruments, and simulation studies, should be 
presented if they have been performed, as described 
under item 8.
Direction of causality (item 13c)
Report any assessment of direction of causality (eg, 
bidirectional MR).
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Example
“The BMI allele score was also associated with 25(OH)
D concentrations (per unit increase −0.06%, [−0.10% 
to −0.02%], p=0.004) while no association with 
BMI was seen for either the vitamin D synthesis or 
metabolism allele scores (per allele in synthesis score: 
0.01% [−0.17% to 0.20%], p = 0.88, metabolism allele 
score: 0.17% [−0.02% to 0.35%], p=0.08]).”40
Explanation
Bidirectional MR can be used to orient the causal 
direction(s) of effect. This is done using two 
independent sets of genetic variants related to the 
exposure and outcome separately, and performing MR 
analyses to appraise causality in both directions.102
Compare with non-MR analyses (item 13d)
When relevant, report and compare with estimates 
from non-MR analyses.
Example
“Using the Durbin-Wu-Hausman test for endogeneity, 
we found weak evidence that the instrumental variable 
estimate using the time spent in education allele score 
differed from the observational point estimate (Durbin-
Wu-Hausman P=0.06), with the instrumental variable 
estimate suggesting a larger negative association.”87
Explanation
Authors should describe important differences 
between MR estimates and estimates from non-MR 
analyses. Each study design has different types of 
biases and could have different degrees of statistical 
power. Putting the MR results in context will help 
readers understand if the strengths and weaknesses 
of MR allow for results that support or contradict 
previous evidence. In general, causal inference can 
be presented in a triangulation framework, evaluating 
the overall body of evidence from several different 
approaches.103 104
Additional visualisation of results (item 13e)
Consider additional plots to visualise results (eg, leave-
one-out analyses).
Example
“Leave-one-out analysis: each row represents a two-
sample MR analysis of BMI on subjective wellbeing 
using all of the genome-wide significant SNPs 
available from Locke et al. except for the SNP listed 
on the y-axis. The point represents the effect size with 
that SNP removed and the line represents the standard 
error. Leave-one-out analysis was conducted using MR 
Base to identify if any individual SNPs were driving the 
association between BMI and wellbeing . . . The SNP 
with the largest contribution to the effect is rs1421085 
located on chromosome 16 in the second intron of the 
FTO (fat mass and obesity associated) gene. FTO has 
been repeatedly associated with obesity in different 
populations. However, the biological consequences 
of intronic FTO SNPs are still unknown. They are 
currently thought to play a regulatory role in FTO gene 
expression in the hypothalamus. Although research 
is not completely certain of the role of FTO, its large 
effect size and robust association with obesity suggest 
that this gene has the largest effect in the two-sample 
MR because of its BMI effect size rather than because 
of pleiotropic effects.”39 (See example in fig 4; further 
examples are available in web appendix 2.) 
Explanation
Additional plots might also aid in the visualisation of 
results, assessing assumption violation, and detecting 
potential influential or outlier points. These include the 
leave-one-out plot,84 radial plot,105 and plots of each 
genetic variant against their studentised residuals or 
Cook’s distance for outlier assessment.32
Discussion
The discussion should look at the important issues 
pertaining to study interpretation and validity.106 
Structured discussions can help authors avoid over-
interpreting results, and act as a guide for readers.107 108
Key results (item 14)
Summarise key results with reference to study 
objectives.
Example
“Based on comprehensive genetic data from nearly 
450 000 individuals, our study provides evidence that 
differences in body mass index and body fat distribution 
causally influence different aspects of smoking 
behaviour, including the risk of individuals taking up 
smoking, smoking intensity, and smoking cessation. 
These results highlight the role of obesity in influencing 
smoking initiation and cessation, which could have 
implications for public health interventions aiming to 
reduce the relevance of these important risk factors.”51
Explanation
The discussion should begin with a summary of the 
main results and a statement of their importance. This 
section reminds readers of the study questions and its 
primary findings, and helps readers assess whether 
the interpretations that follow are consistent with the 
results. Good practice would be to keep the summary 
in the perspective of the main study objectives and 
focus on the prespecified hypothesis, reporting the 
estimates of the investigated causal association in the 
given population.107
Limitations (item 15)
Discuss limitations of the study, taking into account 
the validity of the instrumental variable assumptions, 
other sources of potential bias, and imprecision. 
Discuss both direction and magnitude of any potential 
biases and your efforts to resolve them.
Example
“As in any Mendelian randomisation analysis, several 
assumptions were made, including that the genetic 
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instruments were associated with the risk factor of 
interest, were independent of potential confounders, 
and could only affect the outcome through the risk 
factor and not through alternative pathways (that is, 
through pleiotropy). We note that the first assumption 
was satisfied because robustly associated gene 
variants were identified from the largest genome 
wide association study for each obesity parameter. 
Whether the other two assumptions held was not 
readily testable, although we conducted thorough 
sensitivity analyses that did not highlight any obvious 
violation of these assumptions. Secondly, a potential 
confounder of our results was population stratification 
by sociodemographic factors. Indeed, it was previously 
shown that the genetic instrument for body mass 
index was associated with various factors related to 
social class among women, including lower annual 
household income and level of deprivation. However, 
no such associations were seen in men. In our study, 
the associations between the genetic instruments 
of obesity and individuals taking up smoking and 
smoking intensity were consistently observed in 
both men and women, separately, and also when 
we excluded SNPs that were potentially linked to 
social deprivation. Therefore, apart from the inverse 
association between body fat percentage and smoking 
cessation observed in women only, population 
stratification by sociodemographic factors would 
not seem likely to explain those results.”51 (Further 
examples are available in web appendix 2.)
Explanation
Authors should address the plausibility of all the 
instrumental variable assumptions, which is especially 
important because many of the assumptions are not 
empirically verifiable. Authors could consider, for 
example, the possibility that (residual) genotype-
phenotype confounders (such as population structure, 
genetic nurture, or assortative mating) could lead 
to a violation of the independence assumption. 
When evaluating a potential violation, authors 
should identify the sources of a violation that could 
affect results and discuss the relative importance of 
different violations, including the likely direction and 
magnitude of any bias they could induce.
Authors should also discuss the precision of the 
results. Imprecision can be due to several features of the 
study design. For example, an instrumental variable 
estimate’s precision from a meta-analysis of multiple 
SNPs will usually be greater than that for a single SNP. 
Suppose SNPs are chosen based on meeting a P value 
criterion in a discovery GWAS. In that case, authors 
should consider factors that affect this GWAS’s power 
to detect SNPs, such as sample size and measurement 
error. Instrumental variable estimates will also be more 
precise when estimated from larger datasets, because 
the standard error for the SNP effect estimates, used to 




Give a cautious overall interpretation of results in the 
context of their limitations and in comparison to other 
studies.
Example
“These Mendelian randomization analyses suggest 
that the causal effect of CETP (cholesteryl ester transfer 
protein) inhibition on the risk of cardiovascular 
events appears to be determined by changes in the 
concentration of apoB-containing lipoproteins rather 
than changes in LDL-C or HDL-C level.”109
Explanation
Provide a cautious interpretation of the overall results. 
When comparing with results from other studies, 
consider how the results might differ from previous 
estimates and discuss possible reasons for these 
differences. Such reasons could include violations 
of instrumental variable assumptions, imprecision, 
different estimation methods, and different studied 
populations. Consider that the overall results should 
be interpreted in the context of other studies that 
assessed the study question using different designs, 
allowing for triangulation of results (see item 13d). 
When interpreting the effect size, discuss assumptions 
underlying any extrapolations of effect size and how 
they may have influenced results.
Mechanism (item 16b)
Discuss underlying biological mechanisms that could 
drive a potential causal association between the 
investigated exposure and the outcome, and whether 
the gene-environment equivalence assumption is 
reasonable. Use causal language carefully, clarifying 
that instrumental variable estimates might provide 
causal effects only under certain assumptions.
Fig 4 | Leave-one-out analysis. Figure reproduced with permission from Wootton et al, 
201839
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Example
“The association between pubertal timing and 
weight status is complex and plausibly bidirectional. 
Increased adiposity in childhood has been linked to 
earlier pubertal maturation, although this relationship 
may be nonlinear in boys. Furthermore, several studies 
report evidence for an association between earlier 
age at puberty and later obesity. Therefore, we sought 
to control for both genetically predicted adult and 
childhood BMI, and we observed a similar magnitude of 
attenuation in the association between pubertal timing 
and risk of MS. However, there is a strong association 
between childhood and adult BMI, which limits the 
exploration of age-specific effects. Nonetheless, 
postpubertal rather than childhood obesity is most 
clearly related to MS susceptibility, making the 
association between pubertal timing and adult obesity 
the most likely mediator of the effect of age at puberty 
on risk of MS. Because it appears that BMI and pubertal 
timing are in the same causal biological pathway, the 
association of the selected genetic variants with both 
exposures represents an example of vertical pleiotropy 
due to shared biological underpinnings and thus does 
not bias the MR estimates.”35
Explanation
While the biological mechanisms that allow genetic 
variants to be used as instrumental variables are often 
unknown, the discussion should consider possibilities. 
Doing so will enable readers to put the MR results 
in context about possible biological mechanisms, 
allowing for a better understanding of the plausibility 
of causal associations.
A common reason why MR estimates do not have a 
straightforward causal interpretation is because it is 
unclear whether the gene-environment equivalence 
assumption (table 2) is plausible (this assumption being 
that differences in the exposure between genetically 
defined subgroups of the population are equivalent to 
differences in the exposure due to an intervention—
that is, the MR form of the consistency assumption).110 
Effects of genetic variants can influence outcomes 
from conception onwards and in a manner that can be 
variable and complex. Various components of growth 
and development could be influenced by the variants, 
whilst their identification through genetic association 
studies is often from association with phenotype 
measured at one time point. The often lifelong 
influence of genetic variants can be different from the 
environmental influences investigated in conventional 
epidemiological studies that are generally experienced 
at defined stages of later life. Differing effects over the life 
course do not lessen the potential use of MR estimates. 
For example, it is possible to separate the effects of 
body mass index in childhood and adulthood on a 
variety of health outcomes using different instruments 
for the two exposure periods.111 Conversely, the long 
term effect of lowered low density lipoprotein (LDL) 
cholesterol can be estimated from early life onwards 
by MR and is double the effect estimate derived from 
randomised trials. This difference probably reflects MR 
providing an estimate of lifelong effects, whereas trials 
provide an effect estimate for period of randomisation, 
which lasts just a few years in cholesterol lowering 
randomised clinical trials. This difference seen between 
estimates relating to lifetime differences and shorter 
term cholesterol lowering is anticipated from the known 
cumulative effect of lipids on atherosclerotic coronary 
disease.112 The fact that similar estimates are seen in 
this regard for a wide variety of non-overlapping sets 
of instruments constructed to match pharmaceutical 
agents for LDL cholesterol lowering adds robustness 
to the interpretation.112 Time dependency of the effects 
of instruments is an important issue that should be 
considered when interpreting MR findings, and is 
well served by viewing this in the context of gene-
environment equivalence.
Clinical relevance (item 16c)
Discuss whether the results have clinical or public 
policy relevance, and to what extent they inform effect 
sizes of possible interventions.
Example
“Although uncertainty remains around the precise 
function of each of the 162 SNPs, their degree of 
pleiotropy with cardiac traits, and the mechanisms by 
which these genetic variants exert their cardioprotective 
influence, conclusions can still be drawn . . . we note 
that interventions should be accompanied by careful 
monitoring for unforeseen side effects, especially in 
those people who may not thrive when forced into 
extended educational settings, which may otherwise 
aggravate health inequalities.”113
Explanation
Investigators should describe the potential impact 
of the results on clinical practice or public policy, if 
any. Because many interventions cannot be tested in 
randomised clinical trials, MR evidence might help 
to better understand the possible causal effect of the 
exposure on the outcome (box 4). Such statements 
should be made with caution and in the light of evidence 
from other sources, such as other observational and 
experimental studies when available. Since clinical 
and policy interventions might have different effect 
sizes compared with the genetic variants included in 
the MR study, extrapolation of this evidence should be 
clearly described and cautious.
Generalisability (item 17)
Discuss the generalisability of the study results (a) to 
other populations, (b) across other exposure periods or 
timings, and (c) across other levels of exposure.
Example
“Our Mendelian randomisation work examined a linear 
relation between vitamin D levels and fracture risk. We 
did not test for the possibility of a threshold dependent 
relation—that is, effects that could be present only 
at very low levels of vitamin D . . . Finally, the non-
significant trend observed for vitamin D towards 
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having increased risk of fracture could be attributed 
to the selection of healthy people (that is, participants 
with very low levels of vitamin D and fracture, as well 
as those who are older, frail, and physically impaired, 
could have been under-represented in the studies 
included in the GWAS meta-analyses). Therefore, the 
vitamin D estimates of the current study cannot be 
generalised to these groups of older people.”41
Explanation
The generalisability of a study is the extent to which 
the study’s results apply to circumstances different 
from the ones in which the study was conducted.117 
For example, findings from a cohort of a specific age 
group collected in the past might not apply to people 
currently in the same age group.118
MR studies can fail to generalise in other ways. For 
example, because genetic variants might not have 
a constant effect over the entire life course, authors 
should consider whether the effect estimate derived 
in the study would generalise to other exposure 
periods. For example, if the effect of the exposure on 
the outcome is time dependent, or only occurs during 
a critical period, MR estimates could be misleading if 
used to guide future interventions if they occur outside 
of this time frame. Likewise, if the effect of an exposure 
on an outcome is cumulative over many years, MR can 
overestimate the effect when compared to short term 
interventions.60 119
Also, MR estimates are directly calculated only for 
the exposure range caused by differences in alleles. 
Applying MR results, therefore, might not generalise 
to a wider exposure range. Further, if the MR estimate 
was derived from a population subgroup, it might not 
be generalisable beyond that subgroup.
Other information
Funding (item 18)
Describe sources of funding and the role of funders in 
the present study and, if applicable, sources of funding 
for the databases and original study or studies on 
which the present study is based.
Example
“Funding: The breast cancer genome-wide association 
analyses were supported by the Government of Canada 
through Genome Canada and the Canadian Institutes 
of Health Research, the Ministère de l’Économie, 
de la Science et de l’Innovation du Québec through 
Genome Québec and grant PSR-SIIRI-701, the National 
Institutes of Health (U19 CA148065, X01HG007492), 
Cancer Research UK (C1287/A10118, C1287/
A16563, C1287/A10710), and the European Union 
(HEALTH-F2-2009-223175 and H2020 633784 and 
634935). All studies and funders are listed in Michailidou 
et al.25 RCR, ELA, BMB, CLR, RMM, MM, DAL, and GDS 
are members of the MRC Integrative Epidemiology 
Unit at the University of Bristol funded by the Medical 
Research Council (grant Nos MM_UU_00011/1, MC_
UU_00011/2, MC_UU_00011/5, MC_UU_00011/6, 
and MC_UU_00011/7). RCR is a de Pass VC research 
fellow at the University of Bristol. This study was 
supported by the NIHR Biomedical Research Centre at 
the University Hospitals Bristol NHS Foundation Trust 
and the University of Bristol. The views expressed in this 
publication are those of the authors and not necessarily 
those of the National Health Service, National Institute 
for Health Research, or Department of Health and Social 
Care. This work was also supported by Cancer Research 
UK (grant No C18281/A19169) and the Economic and 
Social Research Council (grant No ES/N000498/1). SEJ 
is funded by the Medical Research Council (grant No 
MR/M005070/1). TMF is supported by the European 
Research Council (grant No 323195:GLUCOSEGENES-
FP7-IDEAS-ERC). MNW is supported by the Wellcome 
Trust Institutional Strategic Support Award (grant No 
WT097835MF).”120
Explanation
The source of research funding can lead to bias 
or perceptions of bias in the design, conduct, or 
interpretation of research.121 122 This bias is of special 
concern when research is funded by an entity that 
has an interest in outcomes that are favourable to 
its own commercial, academic, or other interests.123 
Authors should disclose all funding sources and 
provide detailed information about the role of funders 
Box 4: Interpretation of causal effect estimates
Various considerations are needed when interpreting 
causal estimates. If the homogeneity assumption is 
plausible, along with the other assumptions (box 2), 
then the causal estimate will represent the average 
causal effect of the exposure on the outcome in the 
studied population. If the homogeneity assumption 
cannot be made, but the monotonicity assumption 
is plausible, then the causal estimate can be used to 
represent the local average treatment effect.86 Caution 
is especially warranted when interpreting effect 
estimates with a binary exposure.114 In this instance, 
the homogeneity and monotonicity assumptions 
are less likely to be plausible. Also, if the exposure 
is a dichotomisation of a continuous risk factor, 
this poses a further threat to the violation of the 
exclusion restriction assumption.114 An additional 
consideration, which is particularly pertinent to the 
two sample MR setting, is whether the causal effect 
can truly be attributed to the binary exposure. For 
example, when two sample MR studies are carried out 
in exposure samples that contain only a small number 
of participants who have experienced the exposure 
in question, it would be misleading to interpret the 
effects as being those of the exposure itself. Instead, 
the causal effect estimate should be interpreted as 
reflecting the effects of the genetic liability to the 
exposure.115 116 Finally, an important component of 
interpretation is defining the time period.60 Usually MR 
studies are interpreted as a so-called lifetime effect 
of the exposure, but some settings (eg, MR studies in 
pregnant women to study prenatal exposures) lend 
themselves to studies of period effects.
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in developing the research question, collecting data, 
analysing data, selecting investigators, reviewing 
results, preparing the manuscript, or approving the 
manuscript for submission or publication. Other 
sources of influence can include employers, political 
appointees, and government researchers. Describing 
the source of funding allows readers to evaluate the 
work’s credibility and trustworthiness in the light 
of any potential influence from funders. Authors 
should disclose funding sources for biobanks or other 
repositories or databases used in their study because 
these entities also have commercial interests that 
might influence research integrity.124 125
Data and data sharing (item 19)
Provide the data used to perform all analyses or report 
where and how the data can be accessed, and reference 
these sources in the article. Provide the statistical 
code needed to reproduce the results in the article, or 
report whether the code is publicly accessible and if so, 
where.
Example
“Data sharing: The data reported in this paper are 
available by application directly to the UK Biobank. 
The genetic associations with the outcomes in the UK 
Biobank and CARDIoGRAMplusC4D consortium are 
provided in the supplementary data. Software code 
in R for implementing the mendelian randomisation 
analysis, including the principal components analysis, 
is provided in the supplementary note.”126
Explanation
Original data are needed by readers or researchers who 
wish to evaluate or replicate analyses. Many funders 
and journals encourage or require data sharing, and 
provide guidance to authors about the content of 
any explicit data sharing statement required by their 
journal. Consensus is building that data sharing is “an 
inseparable part of the research process.”127 Ideally, a 
data sharing plan should be developed when a study 
is being organised and described in the study protocol 
and journal publications. The plan and any subsequent 
data sharing statement in the article should indicate, 
at a minimum, what data are available (eg, individual 
participant data, statistical analysis plan, documents 
related to the study, biobank or other database 
information) and how the data can be accessed. 
Contact information for the person or organisation 
holding the data and a description of the mechanism 
that will be used to share data should be provided. 
The statement should also describe any time limits on 
data availability, processes, and standards applied to 
requests for data (such as requirements for a research 
protocol or review of applications by a review board) 
and, if known, whether a charge is required to obtain 
the data. If the data are available only via federated 
analyses, the authors should consider making this 
clear to readers. When data come from multiple 
sources, and different conditions apply, consider the 
use of a table format instead of a text statement.
Conflicts of interest (item 20)
All authors should declare all potential conflicts of 
interest.
Example
“Competing interests: All authors have completed the 
International Committee of Medical Journal Editors 
(ICMJE) uniform disclosure form at www.icmje.org/
coi_disclosure.pdf. ARC, DG, TT, JV, REW, GH, RM, SS, 
SB, GDS, MVH, IT, and AD declare no support from 
any organisation for the submitted work; no financial 
relationships with any organisations that might have 
an interest in the submitted work in the previous three 
years; no other relationships or activities that could 
appear to have influenced the submitted work. MRM 
reports grants from Pfizer and non-financial support 
from GlaxoSmithKline, outside the submitted work. 
NMD reports grants from ESRC, grants from MRC, 
during the conduct of the study; grants from GRAND/
Pfizer for unrelated research, outside the submitted 
work. AET reports grants from Pfizer, outside the 
submitted work. LDH reports grants from MRC, during 
the conduct of the study. DW reports grants from NIH, 
during the conduct of the study.”89
Explanation
Financial connections between researchers and 
commercial or other entities and firmly held 
ideological or intellectual views can lead to bias in 
the design, conduct, or reporting of study results. 
When such interests are not disclosed, public trust in 
the research enterprise is eroded.128 According to the 
International Committee of Medical Journal Editors, 
“conflict of interest exists when professional judgment 
concerning a primary interest (such as patients’ 
welfare or the validity of research) may be influenced 
by a secondary interest (such as financial gain). 
Perceptions of conflict of interest are as important 
as actual conflicts of interest.”129 Authors should err 
on the side of disclosing all matters that might be 
considered relevant by readers.
Conclusions
The STROBE-MR reporting guideline proposes a 
minimum set of items supporting authors to clearly 
communicate what was planned, what was done, and 
what was found in an MR study. Similar to the STROBE 
guidelines25 26 for the classical epidemiological study 
designs—cohort, case-control, and cross sectional 
studies—the goal is not to be prescriptive of study 
conduct or limit creativity in the field. Rather, the 
STROBE-MR guideline is intended to facilitate clear 
and comprehensive reporting to enable an appraisal 
of a study’s quality, limitations, and generalisability 
of findings. The checklist is not intended as a formal 
tool for assessing the methodological or reporting 
quality of MR studies, and should not be transformed 
into a quality scale.130 131 STROBE-MR should also not 
be seen as a formal guideline to design and conduct 
MR studies. However, some items and text might be 
useful when designing or conducting an MR study, 
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and this E&E document might be useful to inform 
methodological decisions, particularly for researchers 
with less experience in MR research.
We invite readers to comment on STROBE-MR and 
suggest improvements to the checklist, explanations, 
and examples. The checklist and E&E document are 
living documents that we intend to keep up to date on 
a dedicated website (https://www.strobe-mr.org/). We 
encourage journals to endorse these guidelines using 
clear language regarding what they expect from authors 
and include this information in their instructions to 
authors. For example, journals could ask authors to 
submit completed checklists and peer reviewers to use 
them as part of their review.28 The STROBE-MR guidance 
will be included in the EQUATOR Network website 
(https://www.equator-network.org/), which provides a 
comprehensive collection of reporting guidelines and 
other resources.132 In addition, we welcome and wish 
to be involved in initiatives to translate the checklist 
and E&E document to other languages.
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